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Genital sexual arousal, which consists of genital vasocongestion and lubrication, is 
critical to healthy sexual function in women and closely linked with hormone function. 
Oral hormonal contraceptive pills, which are used by over a quarter of reproductive-age 
women in the United States (Daniels, Daugherty, Jones, & Mosher, 2015; Jones, Mosher, 
& Daniels, 2013), contain either both ethinylestradiol and a synthetic progestin, or solely 
a synthetic progestin. Oral hormonal contraceptive pills (OCPs) tend to reduce the number 
of bioavailable androgens through upregulation of sex hormone binding globulin (SHBG; 
Zimmerman, Eijkemans, Coelingh Bennink, Blankenstein, & Fauser, 2014), and they have 
been associated with decrements in self-reported arousal and vaginal lubrication (Hassanin, 
El-Halwagy, Ismail, & Shehab, 2018; Smith, Jozkowski, & Sanders, 2014). The primary 
aim of this dissertation was to examine differences in physiological lubrication and vaginal 
blood flow among women using OCPs with varying androgenic properties, as well as the 
 vii 
possible mediating role of SHBG in these relationships. Participants in this study were 130 
women: 59 naturally-cycling control women, 50 women taking androgenic OCPs, and 21 
women taking antiandrogenic OCPs. Participants watched sexual films while their sexual 
arousal responses were measured, completed questionnaires, and took part in a blood draw. 
Results indicated physiological deficits in women taking either form of OCP, with marked 
inhibitory effects found in women taking antiandrogenic OCPs. Whereas SHBG did not 
meaningfully mediate the relationships between study group and physiological sexual 
arousal response, paths within the models indicated significant relationships among these 
variables. Rates of sexual dysfunction were significantly greater in the antiandrogenic 
group compared to control. These results further elucidate the effect of sex steroid 
hormones on women’s sexual arousal response and suggest the presence of physiological 
sexual side effects of various OCPs. It is recommended that prescribing clinicians consult 
patients on such physiological effects, and future research should examine the maintenance 
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CHAPTER 1: INTRODUCTION 
1.1. FEMALE SEXUAL AROUSAL 
Sexual arousal in women involves both psychological (i.e., subjective) and 
physiological components that prepare the woman’s body and mind for sexual activity 
(Basson, 2015). Subjective sexual arousal has been conceptualized as the “emotional” 
(Chivers, Seto, Lalumière, Laan, & Grimbos, 2010; Parish et al., 2016) or “cognitive” 
(Janssen, Everaerd, Spiering, & Janssen, 2000; Spiering, Everaerd, & Janssen, 2003) state 
of sexual arousal, and was recently defined as positive mental engagement in response to 
a sexual stimulus (Althof et al., 2017). Physiological sexual arousal in women involves 
both genital (e.g., vasocongestion, vaginal lubrication) and nongenital (e.g., increased heart 
rate, sweating, pupil dilation, hardening and erection of the nipples, and flushing of the 
skin) responses. The genital arousal component is integral to female sexual response, as 
genital blood flow and lubrication allow for pain-free penetration in the absence of a genital 
pain disorder. 
The loss or reduction of genital sexual arousal can lead to clinically meaningful 
distress and can detrimentally affect a woman’s sexual function (Leiblum, 2003). Indeed, 
diminished or absent genital arousal was the defining feature of female sexual arousal 
disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM) III, IV and 
IV-TR (American Psychiatric Association, 1980, 1994, 2000) and the International 
Classification of Disease (ICD) 10 and 11 (World Health Organization, 1992, 2019). In the 
recently published ICD-11, female sexual arousal disorder is described as the absence of 
or marked reduction in genital responses (lubrication, genital engorgement, and genital 
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sensitivity), nongenital responses (hardening of the nipples, flushing of the skin, increased 
heart rate, increased blood pressure, and increased respiration rate), and feelings of sexual 
arousal (sexual excitement or pleasure). Similarly, the former DSM-IV characterized the 
disorder as the inability to attain or maintain an adequate “lubrication-swelling” response 
to sexual stimuli. Based largely on these two classification systems, prevalence studies of 
sexual arousal problems in women have focused primarily on self-reported lack of vaginal 
lubrication as a defining characteristic of arousal disorder in women. Studies have found 
that 8-15% of all women and 21-28% of sexually active women report experiencing such 
difficulties (for a review, see Lewis et al., 2010). Similarly, Bancroft and colleagues (2003) 
found that 31.2% of heterosexual women in the United States reported lubrication problems 
over the past month. Within the United Kingdom, the prevalence of persistent lubrication 
problems, lasting three months or more, ranged from 13% (Mitchell et al., 2013) to 28% 
(Dunn, Croft, & Hackett, 1999). Similarly, findings from a recent systematic review and 
meta-analysis indicate a 20.6% prevalence rate of lubrication difficulties among 
premenopausal women (McCool et al., 2016). It should be noted that prevalence studies 
often fail to assess the patient’s distress regarding the arousal concerns, which is a 
necessary criterion for assessing clinical relevance. Studies that do assess distress have 
found that difficulties with lubrication hover around 8% (Burri & Spector, 2011; Shifren, 
Monz, Russo, Segreti, & Johannes, 2008). 
The incidence of lubrication problems is higher among women of peri- or 
postmenopausal years, with one study reporting that 44% of postmenopausal women 
experience persistent or recurrent lubrication problems (Rosen, Taylor, Leiblum, & 
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Bachmann, 1993). When including an assessment of distress associated with lubrication 
problems, the prevalence drops to about 24% (Bancroft et al., 2003; Shifren et al., 2008). 
In part to address this increase in genital concerns occurring during menopause, a related 
but distinct disorder was added to the DSM-5, titled genitourinary syndrome of menopause. 
Genitourinary syndrome of menopause is described as a combination of genital concerns 
(dryness, burning, and irritation), sexual symptoms (lack of lubrication, discomfort or pain, 
impaired function), and urinary symptoms (urgency, dysuria, and recurrent urinary tract 
infections; American Psychiatric Association, 2013). The increase in the prevalence of 
lubrication and other sexual concerns during menopause is thought to be due to hormonal 
changes that accompany this transition (for a review, see Bachmann & Leiblum, 2004). 
1.2. GENITAL SEXUAL AROUSAL IN WOMEN 
Genital sexual arousal, an early physiological event in the overall female sexual 
response, is multifaceted. It is comprised of both central and peripheral components. 
Central components are aspects of sexual arousal regulated by the central nervous system, 
such as brain or spinal cord activation in response to sexual stimuli. Peripheral components, 
on the other hand, are regulated by the peripheral nervous system, which contains both the 
somatic (i.e., voluntary control of the body) and autonomic (i.e., involuntary control of the 
body) nervous systems. Peripheral components of genital sexual arousal include but are 
not limited to, vascular changes such as genital blood flow, smooth muscle relaxation and 
the production of vaginal lubrication. These systems are assumed to be closely related to 
hormone function and activity. The focus of this dissertation surrounded two peripheral 
components of women’s genital sexual response: genital blood flow and lubrication. 
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Within the peripheral nervous system, the autonomic nervous system has been 
found to play a key role in premenopausal women’s sexual arousal (for a review, see 
Meston, 2000). The autonomic nervous system consists of both the parasympathetic and 
sympathetic nervous systems. Meston and colleagues reported that moderate activation of 
the sympathetic nervous system using either exercise (Meston & Gorzalka, 1995, 1996a, 
1996b) or ephedrine (Meston & Heiman, 1998) increased genital arousal in premenopausal 
women. Conversely, suppression of the sympathetic nervous system using clonidine 
inhibited genital arousal (Meston, Gorzalka, & Wright, 1997). The one study to assess the 
effects of sympathetic nervous system activation in postmenopausal women found that 
genital arousal improved in pre- but not in postmenopausal women (Brotto & Gorzalka, 
2002). Whereas such activation appears to be highly relevant to genital sexual arousal in 
premenopausal women, it may be less critical to genital sexual arousal in postmenopausal 
women. This could be due to hormonal shifts (most notable of which is estrogen loss) that 
accompany the menopausal transition (Burger, Hale, Robertson, & Dennerstein, 2007). 
Decreases in estrogen lead to anatomical changes such as a thinning of the vaginal tissue, 
which reduces the amount of blood that can gather in the genital walls and, hence, the 
amount of lubrication produced (as reviewed in Tan, Bradshaw, & Carr, 2012). 
This dissertation examined changes in vaginal lubrication in a sample of 
premenopausal women receiving exogenous sex steroid hormones via oral contraceptive 
pills and compared this novel measure of physiological lubrication against a validated 
measure of vaginal blood flow. The following sections provide a review of the mechanisms 
behind these two peripheral components of women’s sexual arousal response. 
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1.2.1. Mechanisms of Genital Blood Flow 
The vaginal wall consists of three primary layers: the mucosa, muscularis, and 
adventitia. The mucosa consists of a stratified squamous (i.e., thin, flat cells) epithelium 
followed by a layer of connective tissue joining the mucosa and muscularis, referred to as 
the lamina propria. See Figure 1 for a histology slide depicting a cross-section of the 
vaginal tissue in a premenopausal woman, which clearly depicts the distinction of the many 
layers of vaginal tissue. 
 
 
Figure 1. Histology slide indicating the distinct layers of the vaginal tissue in a premenopausal woman. Image 
courtesy of the Department of Histology, Jagiellonian University Medical College. Permission is granted to 
copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, 
Version 1.2 or any later version published by the Free Software Foundation; with no Invariant Sections, no 










tissue of the 
lamina propria 
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As is evident in Figure 1, in premenopausal women, the stratified squamous 
epithelium folds into numerous ridges throughout the vaginal canal and maintains a moist 
coating in an unaroused state (for a review, see Jannini, D’Amati, & Lenzi, 2005). During 
menopause, these ridges flatten and the epithelium thins, decreasing the amount of 
moisture on the vaginal tissue (Traish, Vignozzi, Simon, Goldstein, & Kim, 2018) and 
increasing the risk of traumatization of the tissue and subsequent infection (Naumova & 
Castelo-Branco, 2018). Vaginal tissue has a rich vasculature; the lamina propria contains 
a dense network of thin-walled blood vessels, as well as elastic fibers and nerve supply, 
and the muscularis consists of autonomically-innervated smooth muscle and contains 
numerous blood vessels and arteries. The adventitia, or the outer supportive layer, is rich 
in collagen and elastin, allowing for the easy expansion and elongation of the vaginal canal 
during sexual arousal and childbirth. 
Autonomic nerve fibers within the vaginal tissue itself produce several peptides; 
among them, vasoactive intestinal polypeptide and neuropeptide Y have been identified as 
being particularly relevant to genital blood flow (see Berman, 2005, for a review). 
Following sexual stimulation, vasoactive intestinal polypeptide and neuropeptide Y are 
released from nerve endings. Vasoactive intestinal polypeptide then freely interacts with 
nitric oxide and facilitates smooth muscle relaxation (e.g., Hoyle, Stones, Robson, Whitley, 
& Burnstock, 1996). This relaxation manifests as an expansion of the diameter of local 
blood vessels, which reduces resistance and allows for greater vascular inflow. It is 
generally considered that venous drainage is then reduced, which maintains 
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vasocongestion and increases the length and diameter of the vaginal canal (Munarriz et al., 
2003). 
1.2.2. Mechanisms of Vaginal Lubrication 
Vaginal lubrication is thought to result from increased genital vasocongestion and 
occurs both internally (i.e., within the vaginal canal) and externally (e.g., on the labia). 
Lubrication produced within the vaginal canal is a plasma transudate, which is a thin fluid 
containing few, if any, cells that have been filtered out of the blood plasma due to an 
increase in venous pressure (Damjanov, 2009). External lubrication occurs in the form of 
mucus produced by the Skene’s and Bartholin’s glands. The Skene’s glands are 
homologous with the male prostate gland, both of which consist of similar structures and 
histological makeup. The ducts that lead from the Skene’s glands are located on the anterior 
wall of the vulvar vestibule near the urethral opening (Zaviačič, Jakubovská, Belošovič, & 
Breza, 2000) and secrete a lubricating fluid that contains biochemical markers such as 
prostate-specific antigen, human urinary protein 1, and phosphodiesterase type 5 (Jannini 
et al., 2005). The Bartholin’s glands are analogous to the bulbourethral (Cowper’s) glands 
in males. The mucus-secreting ducts leading from the Bartholin’s glands are located 
slightly posterior and to the left and right of the vaginal opening (Omole, Simmons, & 
Hacker, 2003). Lubrication produced by the Skene’s and Bartholin’s glands slightly 
moistens the labial opening of the vagina and is thought to be minimal (Masters & Johnson, 
1966). Thus, this review focuses on internal lubrication in the form of plasma transudate. 
During sexual arousal, blood supply to the vaginal mucosa (i.e., the first layer of 
the vaginal tissues, which consists of the epithelium and lamina propria) increases, 
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resulting in increased transudate passing through the vaginal epithelium cells (for a review, 
see Giraldi & Levin, 2006). In an unaroused state, vaginal fluid has a relatively high 
potassium and low sodium concentration, with additional, notable concentrations of 
calcium and chloride (Levin & Wagner, 1977; Stamey & Timothy, 1975; Wagner & Levin, 
1978). During sexual arousal, however, the increased transudate passing between cells 
realizes the cells’ capacity for sodium transfer, yielding high concentrations of both sodium 
and chloride (Levin & Wagner, 1977). In line with the basic principles of osmosis, this 
fluid cannot be reabsorbed back into the vaginal epithelium cells as the amount of 
circulating transudate increases and the cells become saturated with sodium. Small droplets 
of plasma transudate thus move through the epithelium and gather on the vaginal surface, 
increasing the overall pH of the vaginal canal (e.g., Berman et al., 2001; Wagner, 1979). 
As the droplets gather, the vagina becomes coated in a moist barrier that protects itself from 
tearing during penetration (Giraldi & Levin, 2006). 
1.3. MEASUREMENT OF FEMALE SEXUAL AROUSAL 
As previously described, sexual arousal consists of both subjective and 
physiological components. Subjective sexual arousal is most often assessed in a laboratory 
setting immediately before and after the presentation of an erotic film with several Likert-
style, self-report questions, though it can also be measured continuously throughout the 
film (Rellini, McCall, Randall, & Meston, 2005). The Likert-style questions gauge a 
participant’s level of “mental arousal” (or the degree to which she feels “turned on”) during 
the erotic film. Measures of physiological nongenital arousal include both self-report scales 
and physiological assessment. Typically, self-report scales assess women’s perceived 
 9 
changes in autonomic arousal, such as increases in heart rate, sweating and flushing of the 
skin (e.g., Heiman & Rowland, 1983), as well as hardening and erection of the nipples. 
Physiological assessments of nongenital arousal include electrocardiogram (to examine 
changes in heart rate), galvanic skin response (to measure phasic sweating responses), and 
eye tracking (to calculate pupil dilation). 
Laboratory-based measures of physiological genital arousal include thermistors and 
thermographic cameras, laser Doppler imaging, ultrasound, magnetic resonance imaging 
and, most commonly used, photoplethysmography (for a review, see Kukkonen, 2015). As 
genital blood flow is paramount to physiological genital arousal through its theorized 
facilitation of both vaginal lubrication and swelling responses, most of these measurement 
devices provide either direct or indirect assessments of genital vasocongestion. 
1.3.1. Labial Thermistor 
The labial thermistor is a small disk that attaches to the labia minora. The disk 
contains a thermometer, which provides a continuous record of changes in surface (i.e., 
labial skin) temperature (Henson, Rubin, Henson, & Williams, 1977). Although surface 
temperature is an indirect measure of blood flow, data provided by the labial thermistor do 
not appear to correlate with more direct measures of blood flow (Prause & Heiman, 2009). 
Despite this, increases in genital temperature as evidenced by the labial thermistor have 
been found to be specific to sexual arousal and correlate well with self-report measures of 
sexual arousal (for a review, see Payne & Binik, 2006). A number of concerns with the 
labial thermistor have been posited, such as the slow return to baseline that prevents 
repeated testing, as well as typical fluctuations in body temperature resulting from 
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environmental and/or menstrual changes that may impact testing (for a review, see 
Kukkonen, 2015). 
1.3.2. Thermographic Cameras 
Thermographic cameras remotely record temperature though the assessment of 
infrared radiation. Radiation emission is directly related to the temperature of the emitting 
object or body, and the temperature of the object or body can be calculated based on the 
detected level of radiation (as reviewed in Lahiri, Bagavathiappan, Jayakumar, & Philip, 
2012). The remote nature of testing is widely regarded as a benefit of thermographic 
cameras, as it eliminates the need for the measurement device to come in direct contact 
with the participant. Similar to the labial thermistor, thermographic cameras serve as an 
indirect measure of blood flow, and genital temperature has been found to increase 
specifically to sexual, opposed to neutral, humorous or anxiety-provoking, stimuli 
(Kukkonen, Binik, Amsel, & Carrier, 2007, 2010). There are also a few limitations to 
thermographic cameras that should be mentioned. As with the labial thermistor, there is a 
relatively slow return to baseline period required for repeated testing. A study by Prause 
and Heiman (2009) suggested that genital temperature requires a 10-minute period to fully 
return to baseline (i.e., the temperature of an unaroused state). Thermographic cameras also 
require a consistent ambient temperature and are sensitive to environmental and bodily 
changes in temperature that may be unrelated to sexual arousal. This could complicate the 
ability to compare results from different individuals, clinics, or laboratories, as not all 
testing environments may have the same ambient temperature. 
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1.3.3. Laser Doppler Imaging 
Laser Doppler imaging is the only direct assessment of superficial (i.e., two to three 
millimeters under the skin) blood flow that does not require genital contact (Waxman & 
Pukall, 2009). Laser Doppler imaging functions by projecting an infrared laser beam over 
the skin (Turner, Galarraga, & Khan, 2012). As the light interacts with blood moving under 
the skin, its speed and direction changes, which is detected and recorded by the device 
(Wardell, Jakobsson, & Nilsson, 1993). Laser Doppler imaging has been found to 
discriminate between clinical and non-clinical samples (Boyer, Pukall, & Chamberlain, 
2013), and detects changes in blood flow that are specific to sexual, rather than neutral, 
humorous, or anxiety-provoking, stimuli (Waxman & Pukall, 2009). One notable drawback 
to the use of laser Doppler imaging is that it takes roughly two to three minutes to complete 
a single scan (Styles, MacLean, Reid, & Sultana, 2006), therefore continuous measurement 
throughout a film is not possible. 
1.3.4. Ultrasound Probes 
The use of ultrasound probes to assess clitoral blood flow has also been examined, 
though is not generally considered a promising tool for assessing women’s sexual arousal 
in a research context (Kukkonen, 2015). One reason for this is that ultrasound probes must 
be held in place by a trained sonographer throughout testing, which may be considered 
invasive and unappealing to potential participants. The need for a trained sonographer also 
severely limits the ability for this tool to become widespread, as many sexual 
psychophysiological researchers and clinicians do not have such training. Researchers who 
have used these probes, however, have found that they are sensitive enough to detect 
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increases in clitoral blood flow in response to pharmacological agents (Bechara et al., 2003; 
Caruso et al., 2006). However, the device does not appear to differentiate sexual arousal 
from control conditions (e.g., humorous stimuli) and has not been found to correlate 
significantly with subjective sexual arousal (Kukkonen et al., 2006). 
1.3.5. Magnetic Resonance Imaging 
Few studies have examined the use of magnetic resonance imaging for the 
assessment of genital sexual arousal in women. Magnetic resonance imaging provides an 
examination of the genital structure through the use of magnetic fields that develop images 
of the body (R. W. Brown, Cheng, Haacke, Thompson, & Venkatesan, 2014). Change in 
clitoral blood volume, opposed to changes in other genital structures such as the labia, 
appears to be the most reliable index of sexual arousal provided by this method (Maravilla 
et al., 2005). Indeed, clitoral blood volume has been found to increase during exposure to 
sexual stimuli (Maravilla et al., 2005; Suh et al., 2004), however, the specificity of this 
response has yet to be evaluated. The use of magnetic resonance imaging is costly and 
accessibility is limited, therefore it is unlikely to become a widespread tool to measure 
sexual arousal (Kukkonen, 2015). 
1.3.6. Vaginal Photoplethysmography 
The most widely implemented measure of physiological sexual arousal in women 
is the vaginal photoplethysmograph, which has been used in over 200 published studies to 
date. The vaginal photoplethysmograph is a clear, acrylic, tampon-shaped device used to 
detect changes in tissue engorgement. The vaginal photoplethysmograph was designed to 
be easily inserted by the participant, and a positioning shield can be placed on the device’s 
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cord in order to standardize the location and depth of insertion between uses (Laan, 
Everaerd, & Evers, 1995). The vaginal photoplethysmograph contains a light-emitting 
diode or transistor that emits either infrared or incandescent light. After emission, the light 
reflects off of blood that has gathered in the capillary bed of the vaginal canal and is 
subsequently detected by the device (Hoon, Wincze, & Hoon, 1976; Sintchak & Geer, 
1975). The quantity of light that is detected by the device directly relates to the transparency 
of the vaginal tissue, where less transparency (i.e., more blood in the genital walls) 
facilitates greater amounts of back-scattered light. Therefore, the device serves as an 
indirect measure of vasocongestion. Vaginal pulse amplitude (VPA), the corresponding 
unit of physiological sexual arousal provided by the device, is believed to reflect phasic 
changes in vaginal engorgement with each heartbeat, such that greater pulse amplitudes 
indicate greater engorgement (e.g., Geer, Morokoff, & Greenwood, 1974). Vaginal 
photoplethysmography is both a sensitive and reliable index of women’s physiological 
sexual arousal (Laan et al., 1995). Vaginal pulse amplitude has consistently been found to 
increase specifically during exposure to erotic stimuli rather than anxiety-provoking 
stimuli, which also produce physiological activation (e.g., Hamilton & Meston, 2011; Laan 
et al., 1995; Prause & Heiman, 2009). This suggests that VPA is uniquely sensitive to 
sexual, as opposed to bodily, arousal. 
1.3.7. Vaginal Lubrication 
There is currently no common objective measurement of women’s lubrication 
response implemented by researchers (Graham, 2010). Although objective measures (e.g., 
cotton swabs) have been used in animal models, their application to humans has been 
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limited. Early studies of vaginal lubrication primarily examined the quantity of lubrication 
during unaroused states using cotton swabs (Stone & Gamble, 1959), tampons (e.g., 
Godley, 1985; Odeblad, 1964; Preti, Huggins, & Silverberg, 1979), and evaporimeters 
(Wagner, 1979). Cotton swabs and tampons function as methods of collecting vaginal 
lubrication, whereas evaporimeters measure humidity within the vagina. Cotton swabs and 
tampons are historically the most commonly used methods of assessing vaginal lubrication, 
though their use in humans has not been reported in the scientific literature for at least three 
decades. Tampons and cotton swabs are weighed on a calibrated scale before and after 
being worn in the vaginal canal and may be worn for varying lengths of time, such as six 
(Preti et al., 1979) to eight hours (Godley, 1985). Using tampons, Preti and colleagues 
(1979) and Riley and Riley (1983) observed substantial increases in lubrication within the 
vaginal canal following sexual stimulation and orgasm, respectively. However, due to the 
high absorbency and wicking capacity of tampons and cotton swabs, repeated testing is not 
recommended as the vaginal epithelium may become atypically dry (Levin, 2003). 
Significant increases in vaginal moisture following sexual stimulation have also been 
detected by an evaporimeter, which is a device that measures the humidity of the vaginal 
canal (Wagner, 1979). 
Recently, the use of litmus strips has been assessed in the measurement of vaginal 
lubrication (Carranza-Lira et al., 2003; Dawson, Sawatsky, & Lalumière, 2015). Carranza-
Lira and colleagues (2003) measured changes in basal vaginal lubrication (i.e., lubrication 
during an unaroused state) in 40 postmenopausal women before and three months after 
initiating a regimen of estrogen-based hormone replacement therapy. The litmus strips, 
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which were placed at the base of the vaginal introitus (i.e., vaginal opening), detected 
significant increases in lubrication from pre- to post-treatment, suggesting that the 
estrogen-based treatment was effective at increasing vaginal lubrication. Using litmus 
strips and the protocol outlined by Carranza-Lira and colleagues (2003), Dawson and 
colleagues (2015) later examined changes in lubrication in response to sexual and 
nonsexual stimuli in a small sample (N = 19) of sexually healthy, premenopausal women. 
Significantly greater levels of lubrication were found following the sexual films in 
comparison to the nonsexual films, suggesting that the litmus strips are sensitive enough 
to detect lubrication produced in response to sexual arousal. 
Studies using litmus strips to measure vaginal lubrication have a few limitations. 
One drawback to their use, for example, is that they are not commonly ruled. Rather, the 
length of discoloration (which indicates moisture absorbed by the paper) must be measured 
with calipers. This requires the use of additional equipment and may have the potential to 
introduce measurement error. Additionally, as litmus strips were not designed for the 
assessment of moisture production but rather the pH of a liquid, the wicking capacity will 
vary based on the composition of the strip; rates of water absorption vary within and 
between plastics and paper (e.g., Gáspár, Benko, Dogossy, Réczey, & Czigány, 2005; GE 
Healthcare, 2020). This could lead to inconsistent measurements across clinics and 
laboratories. 
In an effort to circumvent these issues, Handy and Meston (2018a) introduced the 
use of the Schirmer Tear Test strips for measuring vaginal lubrication. These strips are 
approved by the Food and Drug Administration for the clinical assessment of dry eyes, and 
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are also commonly used in clinical research examining moisture produced by mucous 
membranes such as the eyes (e.g., Sall, Stevenson, Mundorf, & Reis, 2000), nose (e.g., 
Lindemann et al., 2014) and mouth (e.g., López-Jornet, Camacho-Alonso, & Bermejo-
Fenoll, 2006). These test strips are ruled in millimeters, which alleviates the need for 
calipers or other measurement devices and may facilitate more accurate interrater 
reliability. They were designed with the intention of measuring moisture production and 
are made from Grade 41 quantitative filter paper, which is a type of ashless filter paper that 
facilitates fast and consistent wicking throughout the test strip. 
Handy and Meston (2018a) assessed the utility of the Schirmer Tear Test strips for 
measuring vaginal lubrication in a sample of 64 women with (n = 32) and without (n = 32) 
sexual arousal concerns. In that study, both groups of women exhibited significant 
increases in physiological vaginal lubrication in response to a sexual film. However, no 
between-group differences were observed for pre- nor post-film levels of lubrication. 
Moderate correlations were found between physiological lubrication and perceived genital 
arousal (r = .41) and lubrication (r = .30); similar correlations between physiological 
lubrication and perceived genital arousal were reported by Dawson et al. (.51; 2015) and 
Sawatsky et al. (.37; 2018) with litmus test strips. Use of the Schirmer Tear Test strips 
appears to be a viable option for assessing physiological lubrication in women. As the 
Handy and Meston (2018a) study was preliminary in nature, more research is needed to 
determine the psychometric properties of this application. 
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1.4. HORMONAL MODULATION OF GENITAL SEXUAL AROUSAL 
Sex steroid hormones are critical to women’s sexual function, and large quantities 
of androgen, estrogen, and progesterone receptors are present in vaginal tissue (Hodgins, 
Spike, Mackie, & MacLean, 1998). The term ‘androgen’ refers to a variety of sex steroid 
hormones including dehydroepiandrosterone, androstenedione, testosterone, and 5α-
dihydrotestosterone (Bolour & Braunstein, 2005). To properly reflect the terminology used 
in the scientific literature (e.g., Davis, Worsley, Miller, Parish, & Santoro, 2016), the term 
‘androgen’ is used in this dissertation as a generic reference to any of its forms (e.g., 
testosterone) or precursors (e.g., dehydroepiandrosterone). 
Androgens have been shown to facilitate both sexual desire and physiological 
sexual arousal (see Davis et al., 2016, for a review) whereas estrogens facilitate arousal 
and appear to have little to no effect on desire (see Santoro, Worsley, Miller, Parish, & 
Davis, 2016, for a review). Estrogens are potent sex steroid hormones that are critical to 
female fertility, reproductive health, and sexual health. Estradiol, a secreted hormone, 
modulates the structure and function of genital tissues (as reviewed in Hobeika, Armouti, 
Kala, & Stocco, 2020). Specifically, estrogens have vasodilatory and vasoprotective effects 
that regulate blood flow into and out of the vagina and clitoris. Reductions in estradiol have 
been associated with reduced vaginal blood flow, which likely results in reduced vaginal 
lubrication (Nappi & Polatti, 2009). Progestins are thought to moderate the forceful effects 
of estrogens on vaginal tissue (Rosenfield, Cooke, & Radovick, 2014) and may inhibit 
smooth muscle cell growth (Kayisli et al., 2015) and, in turn, vasodilation and lubrication. 
As precursors to the biosynthesis of estrogens, androgens are also important for the vitality 
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of vaginal tissues and are necessary for vaginal function (Cohen & Goldstein, 2016). The 
following sections review key hormonal pathways in women’s genital sexual arousal 
response. 
1.4.1. Sex Steroid Hormones and Genital Blood Flow 
Sex steroid hormones influence genital vasocongestion through two primary 
mechanisms: by 1) maintaining the structural and vascular integrity of the vaginal tissue, 
and 2) regulating the expression of neurotransmitters and proteins that facilitate blood flow. 
1.4.1.1. Hormones and the Structural Integrity of the Vaginal Tissue 
Estrogens and androgens play important roles in maintaining the physiological 
integrity of many tissues, including vaginal tissue (S. R. Davis & Tran, 2001; McEwen, 
1999). They do so by regulating distinct cellular processes within the tissue of the vagina, 
such as the growth and function of neurons, blood vessels, smooth muscle, and cells within 
the endothelium and epithelium (for reviews, see Davis et al., 2016; Santoro et al., 2016). 
This keeps capillary beds lush and vaginal tissue healthy. This relationship is clearly 
evidenced in women transitioning through menopause; decreases in estrogen levels often 
lead to a thinning of the vaginal tissue (for a review, see Bachmann & Leiblum, 2004) and 
difficulties with sexual function (Dennerstein, Randolph, Taffe, Dudley, & Burger, 2002). 
Researchers have suggested that estrogen is particularly important for the 
maintenance of the vaginal mucosal epithelium (I. Goldstein, Traish, & Kim, 2004). For 
example, one study examined the potential differential effects of various sex steroid 
hormones on tissue structure within the rat vagina (Pessina, Hoyt, Goldstein, & Traish, 
2006). In this study, rats were ovariectomized to isolate hormonal effects and were 
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provided with varying quantities and combinations of estradiol, progesterone, and 
testosterone over the course of two weeks. Estradiol increased the thickness of the vaginal 
epithelium to a thickness that was greater than that of non-ovariectomized rats, whereas 
the administration of either progesterone or testosterone did not influence epithelial 
growth. However, the authors stated that the co-administration of estradiol plus 
progesterone or testosterone yielded tissue most similar to that of non-ovariectomized rats. 
That is, whereas the treatment of estradiol alone produced atypical thickening of the 
epithelium, the co-administration of estrogen and progesterone or testosterone facilitated 
typical, or comparatively less, epithelium growth. When examining the muscularis, which 
is the middle layer of the vaginal wall made up of smooth muscle, improvements were only 
seen in rats that received estradiol alone. In fact, the co-administration of estradiol and 
progesterone or testosterone buffered these effects, yielding thinner tissue than that seen in 
the estradiol-alone group. This suggests that estradiol is critical to vaginal tissue structure, 
and testosterone and progesterone may moderate these effects. This improvement in tissue 
structure likely mediates improvements in genital blood flow, as fuller tissue allows for a 
greater density of capillary beds and increased blood supply to the genitals (see Mac Bride, 
Rhodes, & Shuster, 2010, for a review). 
Research has also suggested that androgens may be relevant to the maintenance of 
the vaginal epithelium. In one study examining this topic, twenty-one postmenopausal 
women with breast cancer were treated with intravaginal testosterone in doses of either 150 
or 300 micrograms (μg) daily for 28 days, at which point a vaginal maturation index 
assessment was performed (Witherby et al., 2011). The vaginal maturation index is the 
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ratio of parabasal (i.e., immature cells that are not affected by estrogen and progesterone) 
to superficial (i.e., mature cells that have been affected by estrogen) cells in the vaginal 
epithelium, where greater vaginal maturation index scores indicate greater amounts of 
estrogen stimulation (for a review, see McEndree, 1999). In the group of women receiving 
the 300 μg dose, the vaginal maturation index increased from 20 to 40%, indicating that 
topical testosterone facilitated the beneficial effects of estrogen on the vaginal epithelium. 
Women also reported significant decreases in vaginal dryness over the course of the study. 
This suggests that bioavailable androgens aide estrogen in stimulating (i.e., interacting 
with) vaginal tissue. Therefore, the presence of both estrogens and androgens appears to 
benefit vaginal tissue structure. 
1.4.1.2. Functional Modulation of Vasocongestion 
Sex steroid hormones also modulate vascular components of vaginal tissue by 
regulating the activities of neurotransmitters and proteins such as vasoactive intestinal 
polypeptide and nitric oxide. Vaginal tissue has a dense supply of vasoactive intestinal 
polypeptide and nitric oxide immunoreactive fibers (Hoyle et al., 1996), and their activities 
appear to be largely hormone-dependent. For example, research has shown that vasoactive 
intestinal polypeptide fails to increase vaginal blood flow in estrogen-deprived women 
(Palle, Bredkjœr, Fahrenkrug, & Ottesen, 1991). Palle et al. (1991) provided exogenous 
vasoactive intestinal polypeptide to six postmenopausal women receiving hormone 
replacement therapy and six postmenopausal women who were not receiving hormone 
replacement therapy and measured changes in vaginal blood flow. Significant increases in 
vaginal blood flow were evidenced only in women receiving hormone replacement 
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therapy, suggesting that the sex steroid hormones estrogen and progestin influence 
vasoactive intestinal polypeptide function. This, in turn, appears to facilitate 
vasocongestion. Similarly, animal models indicate that estrogen is critical for nitric oxide-
dependent smooth muscle relaxation (H. W. Kim, Kim, Seo, & Lee, 2002), vaginal blood 
flow (S. W. Kim et al., 2004) and lubrication (Min et al., 2003). In a study conducted by 
Berman, McCarthy, and Kyprianou (1998), estrogen replacement therapy resulted in 
significant increases in nitric oxide expression in ovariectomized compared to intact 
animals. The authors posited that estrogen may be necessary for the regulation of vaginal 
nitric oxide expression and that nitric oxide expression may modulate vaginal blood supply 
and relaxation of smooth muscles (c.f. Al-Hijji, Larsson, & Batra, 2000). 
In addition to estrogens, androgens are important to genital blood flow in women. 
Not only have androgen receptors been found throughout the vaginal tissue (Baldassarre et 
al., 2013), but androgens are also precursors in estrogen biosynthesis (Simpson, 2003). In 
other words, estrogens are formed through the aromatization of various androgens. 
Androgens also have vasodilatory effects (Aversa, Isidori, Spera, Lenzi, & Fabbri, 2003), 
which enhance blood flow and likely subsequent lubrication. The precise role of androgens 
on vaginal blood flow and tissue structure is currently unknown (Berman et al., 2003), but 
researchers have theorized that androgens and estrogens may interact to facilitate sexual 
arousal. To examine this, Min and colleagues (2002) treated ovariectomized animals with 
either estradiol or testosterone and measured changes in genital blood flow. Compared to 
non-ovariectomized animals, significant increases in genital blood flow were found only 
in those treated with estradiol; treatment of testosterone did not restore genital blood flow. 
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Unfortunately, combination treatments were not examined in this study, though these 
results corroborate findings presented in Pessina et al. (2006) and Witherby et al. (2011). 
Thus, it is likely that interactions between androgens and estrogens are most beneficial to 
maintaining healthy vaginal tissue and blood flow in women. 
1.4.2. Sex Steroid Hormones and Vaginal Lubrication 
The effect of hormones on vaginal lubrication is largely thought to be secondary to 
the effects of hormones on the vaginal structure and vascular functions. As reviewed above, 
animal models indicate that estrogens and androgens modulate genital blood flow and 
therefore the production of lubrication (e.g., Min et al., 2002). Some direct effects of sex 
steroid hormones on lubrication have been noted in the literature (for a review, see 
Burrows, Basha, & Goldstein, 2012), though their exact acting mechanisms are unknown. 
For example, androgens have been found to play a necessary role in the glycoprotein 
synthesis required for vaginal mucification (Kennedy & Armstrong, 1976), which is 
characterized by changes in the cells of the epithelium from squamous (i.e., flat) to 
columnar (i.e., tall), mucus-secreting cells (for a review, see Westwood, 2008). Thus, a 
relative androgen deficiency, which could be manifest in low levels of bioavailable 
androgens, may contribute to vulvar and vaginal dryness. 
In addition to androgens, estrogens appear to be beneficial for vaginal lubrication. 
In a prospective, randomized control trial examining the effects of ethinylestradiol on 
sexual function in postmenopausal women, Sarrel (1990) reported that those treated with 
ethinylestradiol reported improvements in vaginal blood flow and dyspareunia, which 
refers to difficulty or pain associated with vaginal penetration (Heim, 2001). However, 
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when these women were treated with the progestin medroxyprogesterone, decreases in 
vaginal blood flow and increases in dyspareunia were found. Similar beneficial effects of 
estrogens in combination with androgens on dyspareunia and vaginal lubrication have been 
reported by others (Sherwin & Gelfand, 1987). Estrogens and androgens may therefore 
positively impact vaginal dryness and dyspareunia, and progestins may blunt these 
beneficial effects (Sarrel, 1990, 2002). 
1.5. ORAL CONTRACEPTIVE PILLS 
The use of animal models in research has facilitated a substantial body of literature 
elucidating the influence of hormones on sexual arousal. Studying women who are 
currently using hormonal contraceptives offers an alternative and complementary means 
to animal models for exploring this topic. Oral contraceptive pills (OCPs) are the most 
common form of hormonal contraception, with a prevalence rate of 28% among 
reproductive-age women in the United States (Daniels et al., 2015; Jones et al., 2013). 
Variations in women’s sexual arousal response by the hormonal composition of OCPs were 
the primary focus of this dissertation. 
1.5.1. Conception and Contraception 
Pregnancy occurs when a sperm fertilizes an egg, which then successfully implants 
in the uterine lining. Prior to ovulation, estrogen levels peak, which causes the pituitary 
gland to release a surge of follicle stimulating hormone and luteinizing hormone (for a 
review, see Watson & Stacy, 2011). The rise in follicle stimulating hormone facilitates the 
maturing of eggs within the ovaries (as reviewed in Hillier, 1994). Once mature, a single 
egg from one ovary is released, and the body reabsorbs the remaining matured eggs. The 
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release of luteinizing hormone triggers the thickening of the uterine lining in preparation 
for the implantation of a fertilized egg (Watson & Stacy, 2011). 
The mature egg travels from the ovary through the fallopian tubes, where a sperm 
may fuse with and fertilize the egg. After fusion, the cells within the egg begin dividing 
and the egg continues traveling through the fallopian tubes towards the uterus, where it 
embeds within the uterine lining (see Marieb & Hoehn, 2016, for a review). The follicle 
that released the egg transforms into a corpus luteum, which is a cluster of sex steroid 
hormone-producing cells. The corpus luteum induces is a large surge in progesterone and 
a small increase in estrogen, which assists in the production of the uterine lining and 
protects against shedding (i.e., menstruation; Watson & Stacy, 2011). Specifically, the 
surge in progesterone initiates the transformation of the uterine lining from proliferative to 
secretory, reflecting increased thickness of the lining in preparation for egg implantation. 
If no egg implants within the walls, progesterone levels fall, the endometrium breaks down, 
and the menstrual cycle resumes (see Hobeika et al., 2020, for a discussion). 
Whereas non-hormonal forms of contraception work by preventing sperm from 
reaching the egg (e.g., condoms) or by blocking the reproductive function (i.e., surgical 
sterilization), hormonal methods (e.g., some intrauterine devices, OCPs) operate by either 
preventing an egg from being released or preventing a fertilized egg from implanting in the 
uterus. Oral contraceptive pills contain synthetic hormones. There are two main classes of 
OCPs: combined OCPs, which contain synthetic estrogen and progestin, and progestin-
only pills. The exogenous hormones provided by both combined OCPs and progestin-only 
pills are metabolized in the liver and, in response to this, the liver increases the production 
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of the protein sex hormone binding globulin (SHBG; for a review, see Stuckey, 2008). As 
the name suggests, sex hormones bind to SHBG and are rendered inactive. Of estrogens, 
progesterone, and androgens, androgens have the highest affinity for SHBG and are thus 
most likely to bind to this globulin and become inactive (Rosner, 1991). Certain progestins 
(e.g., doestrogel) increase liver production of SHBG to a greater extent than others (e.g., 
levonorgestrel); the production of SHBG will increase or decrease based on the androgenic 
or antiandrogenic properties of the progestin (see Darney, 1995, for a review). The decrease 
in ovarian production of sex hormones and increase in production of SHBG can result in 
roughly a two-thirds reduction of bioavailable androgens (for a review, see Zimmerman, 
Eijkemans, Coelingh Bennink, Blankenstein, & Fauser, 2014). 
Oral contraceptive pills inhibit the production of follicle stimulating hormone and 
luteinizing hormone within the pituitary gland (Rivera, Yacobson, & Grimes, 1999). 
Without the rise in follicle stimulating hormone levels, follicles do not facilitate the 
maturing and release of eggs from the ovaries, and ovulation is therefore suppressed (Frye, 
2006). The consistently low levels of luteinizing hormone maintain a thin uterine lining 
that is inhospitable to the implantation of an egg if ovulation were to occur. It is for this 
reason that OCPs are often prescribed for the management of menorrhagia, or heavy 
menstrual bleeding (Farquhar & Brown, 2009): a thinner uterine lining will lead to lighter 
menstrual bleeding. 
The inhibition of follicle stimulating hormone and luteinizing hormone also 
significantly reduces the ovarian production of the sex steroid hormones estrogen, 
progesterone, and androgens. As the ovaries are the primary production source of these 
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hormones in women (Hobeika et al., 2020), the bodies of women taking OCPs rely on the 
synthetic hormones within the pill. Many OCPs provide the body with hormones similar 
in concentration to that of a post-ovulatory state (i.e., high doses of progesterone coupled 
with low doses of estrogen; see Rivera et al., 1999), which further protects against 
pregnancy by leading the body to believe that ovulation recently occurred, and an egg 
should therefore not be released. 
1.5.2. Combined Oral Contraceptive Pills 
Combined oral contraceptive pills contain synthetic forms of the hormones estrogen 
and progestin. Almost all combined OCPs contain ethinylestradiol, a synthetic estrogen. 
The concentration of ethinylestradiol varies by brand (typically between 15-50 μg) but is 
most often around 35 μg per pill (van der Westhuizen & van der Merwe, 2011). The 
primary way in which combined OCPs differ from one another is through their progestin 
component. Typical combined OCPs contain progestins from four main families: 
derivatives of 19-nortestosterone (estranes and gonanes), derivatives of 17α-
hydroxyprogesterone (pregnanes), derivatives of 19-norprogesterone (norpregnanes), and 
one derivative of spironolactone (Schindler et al., 2003). As combined OCPs all suppress 
the production of estrogen, luteinizing hormone and follicle stimulating hormone (Rivera 
et al., 1999), they are all considered anti-estrogenic and anti-gonadotropic. The extent to 
which they are antiandrogenic varies by family: derivatives of 19-nortestosterone tend to 
lack androgenic effects, derivatives of 19-norprogesterone have varying degrees of 
androgenic activity, and 17α-hydroxyprogesterone derivatives and drospirenone, the sole 
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derivative of spironolactone, may exert antiandrogenic (i.e., antagonistic) activity 
(Schindler et al., 2003). 
1.5.3. Progestin-Only Pills 
Progestin-only pills contain a progestin without estrogen. For that reason, 
progestin-only pills are particularly suited for women where the estrogen in combined 
OCPs is contraindicated (e.g., women over 35 who smoke cigarettes), for breastfeeding 
mothers, and for older women. Similar to combined OCPs, progestin-only pills also 
suppress the production of estrogen, luteinizing hormone and follicle stimulating hormone 
(Rivera et al., 1999), and are therefore also considered anti-estrogenic and anti-
gonadotropic. Common progestin-only pills contain low doses of 19-nortestosterone 
derivatives gonanes (e.g., levonorgestrel and desogestrel) or estranes (e.g., norethindrone 
or ethynodiol diacetate). To minimize adverse androgenic effects (e.g., oily skin, weight 
gain), the progestin dose in progestin-only pills is typically lower than that found in 
combined OCPs (de Melo, 2010). 
1.6. ORAL CONTRACEPTIVE PILLS AND SEXUAL FUNCTION 
Given the importance of estrogens and androgens and potential inhibitory role of 
certain progestins in genital blood flow and subsequent lubrication, it is possible that 
combined OCPs containing antiandrogenic progestins (e.g., 17α-hydroxyprogesterone 
derivatives, drospirenone) may negatively impact female sexual arousal. The following 
sections review the current research on the relationship between OCPs and sexual function. 
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1.6.1. Combined Oral Contraceptive Pills and Sexual Function 
Research examining the effects of combined OCP use on sexual function is mixed. 
Whereas some studies report improvements in sexual function (Çetin, Keskin, Verit, & 
Yücel, 2015), a recent review of the literature indicated that decreases in lubrication, 
increases in vestibular pain, and thinning of the labia minora and vaginal introitus are 
common among combined OCP users (Burrows et al., 2012). Indeed, an internet-based 
cross-sectional study examining combined OCP use and women’s sexual function found 
that women taking combined OCPs reported greater levels of vaginal dryness and sexual 
pain as well as decreased lubrication, arousal, pleasure, and orgasm frequency compared 
to women using nonhormonal forms of contraception (Smith et al., 2014). The authors 
suggest that these findings may be related to decreases in bioavailable androgens and direct 
structural effects of combined OCPs on the vagina. Indeed, the type (Pazandeh et al., 2017) 
and dose (Strufaldi et al., 2010) of estrogen have been implicated in sexual health 
outcomes. In an extensive study involving 2,612 healthy medical students, similar findings 
were noted. Women taking combined OCPs scored significantly lower on the Female 
Sexual Function Index (FSFI; Rosen et al., 2000), the gold standard self-report measure of 
female sexual function, than did women using other forms of contraception (Wallwiener 
et al., 2015). However, the authors did not find any effect of estrogen dose or progestin 
type on self-reported sexual function, which suggests that changes in the number of 
bioavailable androgens may not have as large of an effect on sexual function as others have 
suggested (as reviewed in Bachmann et al., 2002). However, Wallwiener and colleagues 
(2015) proffered that any effects of estrogen dose or progestin type on sexual function may 
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have been masked by confounding variables such as frequency of sexual activity. That is, 
if women had not recently (i.e., within the past four weeks, as is required for the FSFI) 
engaged in penetrative vaginal intercourse, their FSFI scores would have been lower than 
those of their counterparts. As this was not controlled for in the Wallwiener et al. study, 
effects of the OCP on FSFI scores could have been overshadowed by the effect of sexual 
inactivity on FSFI scores. 
One limitation of the literature on combined OCP use and sexual function is the 
lack of randomized clinical trials. One recent study that attempted to address this limitation 
examined changes in self-reported sexual function in 340 healthy women who were 
randomized to a common combined OCP (150 μg levonorgestrel and 30 μg 
ethinylestradiol) or placebo for 3 months (Zethraeus et al., 2016). Sexual function was 
measured via the Profile of Female Sexual Function (McHorney et al., 2004), a self-report 
scale assessing various domains of sexual function, at pre- and post-treatment. No 
differences emerged on overall sexual function; however, women in the combined OCP 
group scored significantly lower on the desire, arousal and pleasure domains compared to 
placebo at post-treatment. The authors speculated that there may be a “direct negative 
effect of the progestin component” of combined OCPs on sexual function (pp. 4050). 
1.6.2. Progestin-Only Pills and Sexual Function 
The effect of progestin-only pills on sexual function has received considerably less 
empirical attention than that of combined OCPs. However, a recent study examined self-
reported sexual function (via the FSFI) among roughly 100 women using various forms of 
hormonal contraception (i.e., intrauterine devices, progestin injections, combined OCPs, 
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and progestin-only pills) against 100 women who were not using hormonal contraception 
(Hassanin et al., 2018). Results indicated that FSFI desire, arousal, lubrication, and overall 
sexual function scores were significantly lower among contraceptive users compared to 
controls, and these results were maintained when comparing women taking any OCP (i.e., 
combined OCPs or the progestin-only pill) against controls. When the authors parsed apart 
the type of OCP women were using, they found that the FSFI desire, arousal, lubrication, 
orgasm, and overall sexual function scores were significantly lower in the progestin-only 
pill group compared to controls. Similarly, these domains were significantly lower in the 
progestin injection group compared to controls. The authors suggested that temporary 
contraceptive use can negatively affect sexual function, and this may be particularly true 
for progestin-based contraceptives. Similar reports have been described elsewhere in the 
literature (e.g., Pazandeh et al., 2017). 
1.7. ORAL CONTRACEPTIVE PILLS MAY ALTER PHYSIOLOGICAL SEXUAL AROUSAL 
Only one study to date has prospectively examined the effect of OCP use on 
physiological sexual arousal. In this laboratory-based study, sexual arousal was measured 
in a relatively small sample (N = 16) of premenopausal women who were about to begin a 
self-selected regimen of OCP use (Seal, Brotto, & Gorzalka, 2005). Women watched a 
short neutral-erotic film sequence while their physiological sexual arousal was measured 
continuously through the use of a vaginal photoplethysmograph both before and six weeks 
after beginning OCP use. To determine whether there was an effect of the OCP on 
physiological sexual arousal (i.e., vaginal blood flow), Seal and colleagues compared the 
change in vaginal pulse amplitude (VPA) throughout the neutral-erotic film sequence 
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during the pre-treatment session against that of the post-treatment session. Results 
indicated a significant increase in VPA throughout the neutral-erotic film sequence at pre-
treatment only. After six weeks of OCP use, there was no significant increase in VPA when 
all women’s data were analyzed together. However, when examining women’s responses 
at the individual level, the authors reported tremendous variability at post-treatment; some 
women showed larger increases in VPA throughout the film sequence than they had pre-
treatment, whereas some women showed smaller increases or even some decreases in VPA 
compared to their individual pre-treatment responses. These differences were only evident 
when examining each woman’s responses individually; examining all post-treatment 
responses together masked this variability and yielded no significant increase in VPA. 
It is important to note that participants in this study were taking a variety of OCPs; 
the form of OCP (i.e., combined OCP or progestin-only pill), dose of ethinylestradiol, and 
type and dose of progestin (e.g., norethindrone, levonorgestrel) provided by the pill was 
not regulated. The authors suggested that the variability seen in women’s VPA responses 
at post-treatment might reflect the varying hormonal compositions of the OCPs. Therefore, 
a more comprehensive examination of the potential effects of the estrogen and progestin 
component of OCPs on sexual function is warranted. 
1.7.1. Potential Estrogen-Based Effects 
Estrogens and progestins increase SHBG production, which results in decreased 
bioavailable androgens due to their binding affinity for SHBG. In other words, the more 
SHBG, the fewer bioavailable androgens. Oral contraceptive pills that contain low doses 
of estrogens, or estrogens plus androgenic progestins, have been found to have less of an 
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effect on SHBG than those with high doses of estrogens (Zimmerman et al., 2014). This 
minimized production of SHBG allows for a greater number of bioavailable androgens, 
which may then lead to greater vaginal blood flow and subsequent lubrication through the 
stimulation of androgen receptors. It is, therefore, possible that better physiological sexual 
arousal would be observed in women taking OCPs containing low, rather than high, doses 
of estrogens. 
While this has yet to be studied directly, researchers have examined the relationship 
between combined OCP use and quantity of bioavailable androgens in women with 
hypoactive sexual desire disorder (Warnock, Clayton, Croft, Segraves, & Biggs, 2006). In 
this study, it was found that women who were taking combined OCPs had significantly 
lower counts of bioavailable androgens than did those who were not taking combined 
OCPs. The authors suggested that women taking combined OCPs may have developed 
hypoactive sexual desire disorder as a drug-induced adverse effect due to the low levels of 
bioavailable androgens, as the facilitatory role of androgens in sexual desire is well-
established (Pfaus, 2009). A similar mechanism for adverse physiological sexual side 
effects may also be possible. 
1.7.2. Potential Progestin-Based Effects 
The progestin component of OCPs may also affect sexual arousal. Progestins with 
minimally androgenic or antiandrogenic effects likely increase SHBG. As androgens have 
a high binding affinity for SHBG (Rosner, 1991), greater quantities of SHBG would allow 
for a greater number of androgens to bind and become inactive. This would decrease the 
number of bioavailable androgens. Androgenic progestins, on the other hand, may decrease 
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the estrogen-induced production of SHBG (as reviewed in Sitruk-Ware, 2004). Such a 
decrease in SHBG would limit the number of androgens that could bind and be rendered 
inactive, thus allowing for a greater number of bioavailable androgens. This greater number 
of bioavailable androgens may, in turn, facilitate physiological sexual arousal. 
Indeed, in a multicenter randomized controlled trial, Nathorst-Böös and Hammar 
(1997) found that the coadministration of estradiol and the androgenic progestin 
norethisterone acetate improved vaginal dryness in postmenopausal women to a greater 
extent than tibolone. Tibolone is an orally-administered synthetic steroid with weak 
estrogenic, progestogenic and androgenic properties (Kloosterboer, 2001). A review 
provided by the Global Consensus on Menopausal Hormone Therapy found tibolone to be 
an effective treatment of menopausal symptoms such as bone loss and vaginal atrophy (de 
Villiers et al., 2016); its use in the treatment of sexual arousal dysfunction has yielded 
promising results (Laan, van Lunsen, & Everaerd, 2001; Nathorst-Böös & Hammar, 1997; 
Nijland et al., 2008). Similarly, a meta-analysis examining the effect of OCP use on SHBG 
and androgen concentrations found that second-generation progestins, which are 
notoriously androgenic, were associated with significantly lower levels of SHBG 
production and significantly greater levels of androgen concentration than other 
generations of progestins (Zimmerman et al., 2014). 
In addition to influencing sexual function through altering serum SHBG 
concentrations, supraphysiological quantities of certain progestins may also alter the 
structure of vaginal tissue. A recent, prospective study found that women had decreased 
thickness of the labia minora, reduced diameter of the vulvar vestibule, and reduced clitoral 
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blood flow after three months of receiving an OCP containing the antiandrogenic progestin 
drospirenone (Battaglia et al., 2012). It, therefore, appears as though certain progestins may 
influence sexual function indirectly through the moderation of various effects of exogenous 
estrogens, or directly through alteration of the structure of the vaginal tissue.  
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CHAPTER 2: THE PRESENT STUDY 
2.1. BRIEF OVERVIEW 
The present study examined the effect of exogenous sex steroid hormones on 
physiological sexual arousal in women. Women taking hormonal contraceptives containing 
low doses of ethinylestradiol coupled with either an androgenic or antiandrogenic progestin 
were recruited from the local community. Women with no history of having used hormonal 
contraceptives were also recruited and served as a control group. Participants’ 
physiological sexual arousal in response to erotic films was assessed in two ways. Genital 
blood flow was measured with a vaginal photoplethysmograph, and vaginal lubrication 
was measured with the Schirmer Tear Test strips (Handy & Meston, 2018a). Results from 
these physiological measures were then compared across groups of women. A small blood 
sample (4.0 mL) was collected for quantification of sex hormone binding globulin (SHBG) 
to examine its potential mechanistic role within these relationships. In order to determine 
whether psychological measures of sexual arousal varied across groups, participants also 
provided self-report ratings of subjective sexual arousal and perceived genital arousal in 
response to the erotic films. Participants also provided self-report ratings of sexual function 
and demographic variables. This is the first study to quantify variations in physiological 
lubrication by oral contraceptive use. 
2.2.  SPECIFIC AIMS AND HYPOTHESES 
Aim 1: To test for differences in genital blood flow and vaginal lubrication among 
women using oral contraceptive pills with various androgenic properties. I hypothesized 
that women taking oral contraceptive pills (OCPs) containing low (≤25 μg) doses of 
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ethinylestradiol coupled with an antiandrogenic progestin would exhibit a poorer sexual 
arousal response compared to women taking OCPs containing low (≤25 μg) doses of 
ethinylestradiol coupled with an androgenic progestin. I also hypothesized that women in 
the control group (i.e., who were not using hormonal contraceptives) would exhibit the 
greatest sexual arousal response. 
Given the varying androgenic qualities of different progestins (Regidor, 2014), 
certain progestins may be more likely than others to interfere with healthy sexual function. 
I hypothesized that women taking OCPs with antiandrogenic progestins would have poorer 
physiological sexual arousal compared to those taking OCPs with androgenic progestins 
or control women for two primary reasons. First, progestins combat the estrogen-induced 
increase in SHBG to varying degrees based on the androgenic properties of the progestin. 
Specifically, androgenic progestins have been linked with the least amount of increase in 
SHBG, and antiandrogenic (or minimally androgenic) progestins have been linked with the 
highest increase in SHBG (Zimmerman et al., 2014). For example, the second generation 
androgenic progestin levonorgestrel has been found to increase SHBG production ~50%, 
whereas the third generation antiandrogenic progestin Desogestrel has been found to 
increase SHBG production ~250% (Zimmerman et al., 2014). 
Second, antiandrogenic progestins have been linked with structural decrements of 
the genitals. For example, Battaglia and colleagues (2012) found decreased thickness of 
the labia minora, reduced diameter of the vulvar vestibule, and reduced clitoral blood flow 
after three months of receiving an OCP containing the antiandrogenic progestin 
drospirenone. These structural changes mimic that which is seen during menopause. Given 
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the high prevalence of sexual concerns that onset at menopause (Dennerstein, Alexander, 
& Kotz, 2003) and the large body of literature linking hormonal changes to these sexual 
concerns (as reviewed in Bachmann & Leiblum, 2004), it was anticipated that 
physiological sexual arousal would be most impaired in women taking OCPs containing 
an antiandrogenic progestin. Similarly, physiological sexual arousal was anticipated to be 
least impaired (i.e., the strongest) in women who were not using any form of hormonal 
contraception. 
Aim 2: To examine the mechanistic role of SHBG in the relationship between 
genital blood flow and lubrication and oral contraceptive use. Increased serum 
concentrations of SHBG results in fewer bioavailable androgens (Zimmerman et al., 2014), 
and androgens are critical to healthy female sexual arousal (Davis et al., 2016). This may 
lead to decreased stimulation of androgen receptors within the vaginal tissue, thus 
decreasing vaginal blood flow and subsequent lubrication. It was hypothesized that women 
taking OCPs containing antiandrogenic progestins (i.e., progestins that facilitate SHBG 
production) would exhibit poorer physiological sexual arousal responses compared to 
women who were taking androgenic OCPs or women in the control group (i.e., those who 
are not taking and never have taken OCPs). 
Aim 3: To test for differences in measures of subjective sexual arousal among 
women using oral contraceptive pills with various androgenic properties. In contrast to 
Aim 1, I hypothesized that measures of subjective sexual arousal would be relatively 
similar across the three groups of women. Much research has shown that women tend to 
have low and variable relationships between their subjective and genital arousal response 
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(see Chivers et al., 2010, for a review), though these relationships may vary slightly by 
methodology and statistical approach (e.g., Handy, Stanton, Pulverman, & Meston, 2018). 
Researchers have proposed that women’s experience of subjective sexual arousal 
is influenced by a multitude of factors in addition to genital arousal (Meston & Stanton, 
2018). For example, contextual factors such as relational and partner-specific variables 
have been identified as important aspects of women’s self-reported experiences of sexual 
arousal (Graham, Sanders, Milhausen, & McBride, 2004; Handy, Stanton, & Meston, 
2018). Similarly, individual differences analyses have found that women’s views of their 
sexual selves (Clifton, Seehuus, & Rellini, 2015) and the tendency to pay attention to 
bodily sensations (Velten & Brotto, 2017) significantly influence the relationship between 
women’s subjective and genital sexual arousal. It is, therefore, possible that one’s 
physiological response may be hindered by an OCP while their subjective arousal response 
is not. Indeed, the one study to examine changes in physiological and subjective sexual 
arousal in women before and after beginning an OCP regimen found no changes in 
subjective sexual arousal despite finding slight decreases in physiological arousal (Seal et 
al., 2005). I, therefore, expected that subjective sexual arousal would be similar across the 
three groups of women. 
Aim 4: To test for differences in perceived genital arousal among women using oral 
contraceptive pills with various androgenic properties. Similar to Aim 1, I hypothesized 
that women taking OCPs containing low (≤25 μg) doses of ethinylestradiol plus an 
antiandrogenic progestin would exhibit lower levels of perceived genital arousal compared 
to women who were taking OCPs containing low (≤25 μg) doses of ethinylestradiol 
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coupled with an androgenic progestin. Women in the control group (i.e., who were not 
using hormonal contraceptives) were anticipated to report the greatest amount of perceived 
genital arousal. Despite some suggestions that women are unaware of their genital arousal 
response (e.g., Basson, 2002), more recent research has found that, when measured 
continuously as opposed to using a Likert scale rating, women are able to accurately report 
changes in genital blood flow (Handy & Meston, 2016, 2018b). Therefore, it was expected 
that physiological differences among the three groups of women would also be evidenced 
in self-report measures of perceived genital arousal. 
Aim 5: To explore differences in sexual function among women using oral 
contraceptive pills with various androgenic properties. I hypothesized that women taking 
OCPs containing low (≤25 μg) doses of ethinylestradiol plus an antiandrogenic progestin 
would report the lowest levels of sexual function. I did not expect there to be any large, 
overwhelming differences in sexual function between women taking low (≤25 μg) doses 
of ethinylestradiol coupled with an androgenic progestin and women in the control group. 
I believed it would be likely that, for the majority of women, the physiological effects 
observed in Aim 1 would not be indicative of a sexual dysfunction per se. Rather, the 
effects observed in the present study may reflect pre- or subclinical sexual arousal 
concerns. 
Lower levels of sexual function (but not yet sexual dysfunction) were hypothesized 
to be most likely to occur in the group of women taking OCPs containing low (≤25 μg) of 
ethinylestradiol plus an antiandrogenic progestin as this composition is believed to have 
the most profound effect on physiological sexual arousal. The effect of the OCP containing 
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low (≤25 μg) doses of ethinylestradiol coupled with an androgenic progestin was 
hypothesized not to be strong enough to translate to sexual function that differed 
significantly from that of women in the control group.  
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CHAPTER 3: EXPERIMENTAL DESIGN, MATERIALS, AND METHODS 
3.1. EXPERIMENTAL DESIGN 
This study included a clinical interview and a single experimental session. During 
the experimental session, participants viewed two different neutral and erotic film clips 
while their physiological and subjective sexual arousal responses were measured. Two 
forms of physiological sexual arousal were measured: vaginal lubrication and genital blood 
flow. One form of physiological sexual arousal was measured during each film. The form 
of measurement and films were counterbalanced across study sessions. Subjective sexual 
arousal and perceived genital arousal were measured in relation to each film. The study 
session concluded with the completion of several self-report questionnaires pertaining to 
sexual health and, for a random sampling of women, a small (4.0 mL) blood draw. 
3.2. PARTICIPANTS 
Participants included in the present study were 130 adult, premenopausal, women 
who were either currently taking or had never taken oral contraceptive pills (OCPs) at the 
time of participation. Effort was made to recruit women evenly across the following three 
groups, however, considerably fewer women reported taking antiandrogenic OCPs, thus 
leading to a notably smaller group size: 
Group 1: Low-dose ethinylestradiol plus androgenic progestin (n = 50) 
Group 2: Low-dose ethinylestradiol plus antiandrogenic progestin (n = 21) 
Group 3: Non-hormonal contraceptive control (n = 59) 
Participants were recruited through online advertisements and flyers posted 
throughout the local community (e.g., in laundromats, coffee shops, public bathrooms), as 
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well as through the Human Subjects Pool in Psychology at the University of Texas at 
Austin. These advertisements included basic information regarding inclusion criteria, time 
commitment, and compensation provided. Separate advertisements were created to target 
women who were and were not taking OCPs. All advertisements invited women to call the 
laboratory for a phone eligibility screening, and then if eligible, women were invited to 
schedule a clinical interview and experimental session. As OCPs mimic the body’s natural 
post-ovulatory hormonal concentrations (Rivera et al., 1999), all naturally-cycling women 
were scheduled to participate in the laboratory session during the luteal phase (i.e., between 
days 14 and 28) of their menstrual cycle. This also served as a method of gaining 
conservative estimates of possible between-group differences, as greater levels of sexual 
function are typically observed during the follicular phase of women’s menstrual cycles 
(S. G. Brown, Calibuso, & Roedl, 2011; Caruso et al., 2014; Clayton, Clavet, Mcgarvey, 
Warnock, & Weiss, 1999; Dawson, Suschinsky, & Lalumière, 2012; Graham, Janssen, & 
Sanders, 2000). 
3.2.1. Inclusion and Exclusion Criteria 
3.2.1.1. Inclusion Criteria: 
1. At least 18 years of age. We did not include women under 18 in this study because 
of ethical issues concerning the exposure of minors to sexually explicit content, and 
viewing the sexual films was inherent to study participation. 
2. Fluent in English. Participants were required to be fluent in English as the majority 
of the self-report measures are only available in English and there are not yet 
appropriate alternative instruments. For consistency across participation 
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experiences, the use of translators was not offered to potential non-English-
speaking participants. 
3. Currently sexually active. As the Female Sexual Function Index (Rosen et al., 2000) 
was validated for use in women who are currently sexually active, it was required 
that those who participated in this study had engaged in sexual activity within the 
past four weeks. In order to increase the number of women who were considered 
sexually active, the definition of sexual activity was expanded to include deep 
kissing and petting, as well as partnered or solitary sexual activity. 
4. Currently taking an OCP OR no history of taking any hormonal contraceptives. 
Women who qualified for the low-dose ethinylestradiol plus androgenic progestin 
were required to be taking an OCP containing ≤25 μg of ethinylestradiol coupled 
with an androgenic progestin. Women who qualified for the low-dose 
ethinylestradiol plus antiandrogenic progestin were required to report taking an 
OCP containing ≤25 μg of ethinylestradiol coupled with an antiandrogenic 
progestin. The androgenicity of a progestin was calculated using Dickey’s (Dickey, 
2000) classification of androgenic activity, using a .5 threshold cutoff. Preference 
was given to first and second generation progestins for being classified as 
androgenic, whereas preference was given to third and fourth generation progestins 
for being classified as antiandrogenic. Refer to Table 1 for an index of commonly 





An Index of the Relative Androgenic Activity of Various 
Progestins Found Within Common Oral Contraceptive Pills 
Progestin (1 mg) Relative Androgenicity 
Norethindrone 1.0 
Norethrindrone acetate 1.6 








Note: mg = milligram. The androgenic activity for each progestin is 
relative to 1 mg of norethindrone. For example, the progestin 
levonorgestrel is 8.3 times more androgenic than is norethindrone. Chart 
adapted from Dickey (2000). 
To allow the body to adjust to changes in hormone concentrations, it was 
further required that women in both contraceptive groups had been taking their 
OCP for at least 3 months to qualify for participation (see Battaglia et al., 2012, for 
documentation of vaginal changes after 3 months of OCP use). Furthermore, in 
order to identify whether specific progestin doses contributed to any between-group 
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differences in sexual arousal, it was required that the OCPs included in this study 
were monophasic (i.e., the dose remained the same for each week of active pills). 
Women who qualified for the non-hormonal contraceptive control group must have 
reported no history of ever having used a hormonal contraceptive. See Table 2 for 
a sample list of OCPs and their composition as it relates to each of the two OCP 
groups in this study. 
Table 2. 
Sample List of Oral Contraceptive Pills and Compositions for Each of the Three Study Groups 
Group Brand Name Estrogen Dose (mg) Progestin 
Progestin 



























 Afirmelle 0.020 Levonorgestrel 0.10 0.83 
Aurovela Fe 0.020 Norethindrone acetate 1.00 1.60 
Kaitlib Fe 0.025 Norethindrone 0.80 0.80 
Lo Lestrin Fe 0.010 Norethindrone 1.00 1.00 




























 Gianvi 0.020 Drospirenone 3.00 0 
Loryna 0.020 Drospirenone 3.00 0 
Micrette 0.020 Desogestrel 0.15 0.50 
Nikki 0.020 Drospirenone 3.00 0 
Yaz 0.020 Drospirenone 3.00 0 
 
Note: mg = milligram. All oral contraceptive pills listed in the above Table contain the synthetic estrogen ethinylestradiol. 
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3.2.1.2. Exclusion Criteria: 
1. Over 35 years of age. Only women between the ages of 18 and 35 were included in 
this study in an attempt to increase sample homogeneity. There is a large body of 
literature indicating sexual function declines with age (Hayes & Dennerstein, 
2005), with a specific, negative effect of menopause on sexual desire, arousal, 
lubrication and pain (Dennerstein et al., 2003). The upper limit of age was set at 35 
because I was interested in studying changes in sexual arousal that are associated 
with OCP use rather than sexual dysfunction associated with medical and clinical 
conditions linked to age. 
2. Pregnant or breastfeeding. Sexual function is affected by the physiological and 
hormonal changes that occur as a result of pregnancy, and these changes persist 
into the postpartum period (Serati et al., 2010). Therefore, women who fit this 
criterion were excluded from participation in the present study. 
3. Currently taking beta blockers, antidepressants, anxiolytics, antipsychotics, or any 
medical treatments to enhance sexual response. All of these medications have been 
shown to have sexual side effects (Rosen & Kostis, 1985; Serretti & Chiesa, 2009; 
Stuckey, 2008), which can alter physiological and psychological sexual arousal. 
Therefore, women reporting the use of any of these medications were excluded 
from participation. 
4. Currently receiving exogenous hormones or hormone precursors (e.g., 
dehydroepiandrosterone) other than those provided by the OCP. In an effort to 
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isolate the effects of the hormones provided by the OCP, women receiving 
additional exogenous hormones were not eligible to participate. 
5. Currently experiencing stress or urinary incontinence. The additional liquid within 
the vaginal area due to stress or urinary incontinence can interfere with the 
measurement of vaginal lubrication. Therefore, women with either of these 
conditions did not qualify for participation in this study. 
6. History of a medical condition known to affect hormone function. Similar to above, 
in an effort to isolate the effects of the hormonal OCP, women with a history of a 
medical condition known to affect hormone function (e.g., hyper- or 
hypothyroidism, adrenal hyperplasia, polycystic ovarian syndrome) were deemed 
not eligible to participate in this study. 
7. History of major pelvic surgery that caused nerve damage. Women with pelvic 
nerve damage have significantly different patterns of sexual arousal from those 
without such damage (Vlug et al., 2010). In an effort to eliminate additional sources 
of variability from our study, we excluded from participation women with a history 
of major pelvic surgery (e.g., hysterectomy, vulvectomy, or serious rectal, bladder, 
or abdominal surgery) that resulted in nerve damage. 
8. History of childhood sexual abuse. Childhood sexual abuse was defined as 
unwanted oral, anal or vaginal penetration, or genital touching or fondling before 
age 16 (Rellini, 2008). A large body of literature indicates that childhood sexual 
abuse has negative effects on women’s sexual health (e.g., Rellini & Meston, 2007). 
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Therefore, women with such histories were excluded to reduce variability in our 
data. 
9. History of Sjögren’s or related syndromes. Sjögren’s syndrome is an autoimmune 
disease that causes dryness in the body, including the vaginal area (Bongi, Rosso, 
Orlandi, & Matucci-Cerinic, 2013). As the aim of the present study was to examine 
differences in vaginal lubrication across groups of OCP users, women who 
experienced difficulties with vaginal lubrication due to Sjögren’s or a related 
syndrome were excluded. 
3.2.2. Final Participant Sample 
The sample of 130 women participating in this study satisfied the recommended 
sample size for achieving adequate statistical power. Of the 466 women who called the 
Female Sexual Psychophysiology Laboratory to inquire about the study, 37 women were 
no longer interested in participating after learning more about the required study 
procedures. The remaining 429 callers were screened for eligibility, with 269 women 
calling from the local community and 160 seeking course credit at the University of Texas 
at Austin. 
Of those screened, 263 callers were ineligible for a variety of reasons, including not 
being fluent in English (2.6%); not having engaged in any sexual activities within the past 
four weeks (22.4%); being younger than 18 or older than 35 years of age (4.5%); past, but 
not current, OCP use (17.8%); using an OCP containing >25 µg ethinylestradiol (36.8%); 
using a multiphasic OCP (11.0%); using a progestin-only OCP (1.9%); using additional 
forms of hormones (7.6%); being pregnant or breastfeeding (1.9%); reporting a history of 
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childhood sexual abuse (15.5%); taking beta-blockers, antidepressants, anxiolytics, or 
other medications known to interfere with sexual function (18.2%); having a medical 
condition known to affect hormone function (9.1%); reporting a history of pelvic nerve 
damage (1.5%); experiencing stress incontinence and/or urinary leakage (1.9%); having a 
history of Sjögren’s syndrome or a related autoimmune disorder (1.9%). These percentages 
reflect the total amount of women who were ineligible due to any given criterion. Women 
could, and many did, be ineligible for a variety of reasons. As such, these totals do not 
equal 100%. 
Of the remaining 166 eligible women, 36 women scheduled a visit but either 
canceled or did not attend their study session. The rate of nonparticipation (21.68%) in this 
study is fairly typical for laboratory-based sexual psychophysiological studies (e.g., Lorenz 
& Meston, 2014; Stanton, Boyd, Fogarty, & Meston, 2019).  
3.2.3. Group Differences in Demographic Characteristics 
Continuous variables (i.e., age, age of sexual debut, and relationship length) were 
assessed using a series of multivariate analyses of variance (MANOVA) using base R 
(Team, 2019). Discrete demographic variables (i.e., sexual orientation, relationship status, 
medication use, race, educational attainment, household income) were analyzed using chi-
square tests of independence using the MASS package for support functions and datasets 
for Venables and Ripley’s MASS (Ripley et al., 2019). Efforts were made throughout the 
recruitment process to match study groups on their demographic variables. 
Indeed, it was found that women in the three groups did not differ significantly on 
any of the demographic variables included in the present study. A chi-square test of 
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independence indicated possible between-group differences in race, with more Asian-
identified women within the control group and more Caucasian-identified women within 
the androgenic group (p = .017). This effect is documented in the literature and is believed 
to reflect differing cultural factors, as well as disparities in access to care and treatment 
(Lee, Carvallo, & Lee, 2015; Phares, Cui, & Baldwin, 2012). However, the difference 
observed in the present study was no longer significant after applying a Bonferroni 
correction for the number of comparisons (κ = 9; α/9 = 0.005) and was therefore not 
controlled for in subsequent analyses. 
On average, women who participated in this study were 20.12 years old (SD = 
2.53). Three-quarters (74.61%) of the participants identified as heterosexual, and roughly 
half (55.38%) reported being in a committed relationship. The average relationship length 
was 19.26 months (i.e., roughly 1.5 years; SD = 19.19). The racial makeup of the 
participants included in this study roughly reflected that of the general Austin population, 
with 33.07% of the sample identifying as Caucasian, 29.23% identifying as Hispanic, 
24.61% identifying as Asian, and 9.23% identifying as African American (DataUSA, 
2019). Three-quarters (76.92%) of the participants reported having completed some 
college, and 43.84% reported a household income of less than $50,000. Refer to Tables 3 







Continuous Demographic Characteristics for Participants in Each Study Group 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21  
Demographic 
variable M SD M SD M SD F 
Age 19.98 3.08 20.20 1.88 20.33 2.26 0.182 
Age of sexual debut 16.72 2.64 17.30 1.70 18.09 2.70 2.773 
Relationship length 22.05 24.00 18.39 16.48 14.94 9.84 0.827 
 
Note: M = mean; SD = standard deviation. Relationship length is calculated in months. No significant 
between-group differences emerged for any of these variables. 
 
Table 4. 
Discrete Demographic Characteristics for Participants in Each Study Group 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21  
Demographic variable n % n % n % χ2 
Orientation       11.336 
    Heterosexual/Straight 42 71.18 40 80.00 15 71.42  
    Bisexual 11 18.64 6 12.00 5 23.80  
    Queer 2 3.38 - - 1 4.76  
    Homosexual/Gay/Lesbian 3 5.08 - - - -  
    Other 1 1.69 4 8.00 - -  
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Table 4 (continued). 
Relationship status       12.825 
    Single, not dating 14 23.72 7 14.00 2 9.52  
    Single, dating 14 23.72 16 32.00 2 9.52  
    Committed relationship 30 50.84 25 50.00 17 80.95  
    Married 1 1.69 - - - -  
    Other - - 2 4.00 - -  
Prescription drug use       2.678 
    Yes 9 15.25 14 28.00 5 23.80  
    No 50 84.74 36 72.00 16 76.19  
Ethnicity       2.372 
    Hispanic 24 40.67 14 28.00 9 42.85  
    Non-Hispanic 35 59.32 35 72.00 12 57.14  
Race       18.499* 
    African American/Black 8 13.55 1 2.00 3 14.28  
    Asian 16 27.11 13 26.00 3 14.28  
    Caucasian/White 11 18.64 25 50.00 7 33.33  
    Hispanic 20 33.89 11 22.00 7 33.33  
    Other 4 6.77 - - 1 4.76  
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Table 4 (continued). 
Religion       20.470 
   Atheism/Agnostic 18 30.50 21 42.00 6 28.57  
   Christianity 18 30.50 7 14.00 8 38.09  
   Catholicism 14 23.72 14 28.00 4 19.04  
    Judaism 1 1.69 - - 1 4.76  
    Islam - - 3 6.00 - -  
   Spiritual/New Age 3 5.08 4 8.00 1 4.76  
    Other 5 8.47 1 2.00 1 4.76  
Education       11.338 
    High school diploma/GED 9 15.25 3 6.00 - -  
    Some college 43 72.88 41 82.00 16 76.19  
    College degree  7 11.86 4 8.00 5 23.80  
    Advanced degree - - 2 4.00 - -  
Household income       5.663 
   <$50,000 28 47.45 20 40.00 9 42.85  
    $50,000-$100,000 20 33.89 12 24.00 4 19.04  
    >$100,000 11 18.64 18 36.00 8 3.80  
 
Note: GED = General Education Diploma; MA = Master’s degree. 
* p = 0.017; insignificant after the application of a Bonferroni correction of .005 
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3.2.4. Nature of the Oral Contraceptive Pills Used by Study Participants 
Nearly all women (n = 45; 90%) in the androgenic group reported currently taking 
OCPs containing 20 μg ethinylestradiol. Four participants (8.00%) in this group were 
taking OCPs with 10 μg ethinylestradiol and one (0.19%) with 25 μg ethinylestradiol. For 
the progestin compositions, 34 women (68.00%) in this group were taking OCPs with 1 
mg norethindrone acetate. Ten women (20.00%) were taking OCPs containing 1 mg 
norethindrone, one participant (0.19%) was taking an OCP with .8 mg norethindrone, and 
four (8/00%) participants were taking OCPs containing .1 mg levonorgestrel. Ten women 
(20.00%) in this group reported previous use of a hormonal contraceptive with a different 
hormonal composition than their current OCP. 
One woman (4.76%) taking antiandrogenic OCPs reported taking an OCP 
containing 25 μg ethinylestradiol. The remaining women (n = 20; 95.23%) reported using 
an OCP with 20 μg ethinylestradiol. With regards to progestin use, the majority of women 
(n = 13; 61.90%) were taking an OCP containing 3 mg drospirenone. Seven participants 
(33.33%) were taking an OCP with .15 mg desogestrel and one participant (4.76%) was 
taking an OCP with 35 μg norgestimate. Half of the women (n = 11; 52.38%) in this group 
reported previous use of hormonal contraceptives containing a different composition of 
hormones. 
3.3. EQUIPMENT AND MEASURES 
3.3.1. Clinical Interview 
All participants underwent a brief clinical interview to gather information regarding 
their contraceptive use history (Appendix A) and determine the presence or absence of 
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sexual arousal concerns. During this, the women took part in a brief clinician-administered 
screener, the Female Sexual Dysfunction Diagnosis (FSDD), which based on DSM-IV-TR 
female sexual arousal disorder criteria (Appendix B). The FSDD comprises a series of 
questions regarding their current ability to become sexually aroused. This is to determine 
whether their sexual concern (if present) is arousal-specific, as the present study focused 
specifically on women’s sexual arousal response. These questions examine: a) whether 
women had ever experienced a series of genital sensations; b) the extent to which women 
experience these sensations during sexual activity; c) whether this is situational in nature; 
d) the length of time they have been experiencing this difficulty; e) whether they self-
identify as having an arousal problem; and f) if they are distressed by this problem. Women 
in both of the OCP groups were also asked whether they attributed any of these symptoms 
to their prescribed OCP. 
3.3.2. Manipulation: Neutral and Erotic Videos 
The experimental stimuli consisted of four 10-minute film presentations that were 
each composed of a 4-minute neutral clip and a 6-minute erotic clip. The neutral clips were 
comprised of a 1-minute display of the text “Relax” followed by a 3-minute panoramic 
nature scene. Two of the erotic clips depicted a mixed-sex couple and two clips depicted a 
same-sex couple engaging in sexual activity. Women were allowed to select whether they 
preferred to watch either the mixed- or same-sex films. The erotic clips progressed from 
two minutes of foreplay to two minutes of oral sex to two minutes of vaginal penetration. 
The four 10-minute films were matched for content and presented to women in a 
randomized order. These clips were selected from sexual videos produced and directed by 
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women because past studies indicated that these videos are more successful at producing 
both physiological and subjective sexual responses in women (Laan, Everaerd, van Bellen, 
& Hanewald, 1994). Past studies that used these videos found significant increases in 
women’s physiological and subjective sexual arousal (Handy & Meston, 2016, 2018b). 
3.3.3. Laboratory-Based Measures 
3.3.3.1. Physiological Arousal 
3.3.3.1.1. Genital blood flow 
A vaginal photoplethysmograph was used to assess women’s genital blood flow in 
response to the film presentations. The vaginal pulse amplitude (VPA) signal was sampled 
at a rate of 200 samples per second throughout the entire 240 seconds of neutral film 
presentation and 360 seconds of erotic film presentation. Each wave was recorded in 
millivolts, band-pass filtered (0.5-30 Hz), and recorded on a computer in the next room 
using the software program AcqKnowledge III, Version 3.8.1 and a Model MP150 data 
acquisition unit (BioPac Systems, Inc., Santa Barbara, CA, USA) for analog and digital 
conversion. To ensure that the phototransistor was inserted at the correct depth and 
orientation for each participant, a positioning shield was attached to the cord of the vaginal 
photoplethysmograph. Once the photoplethysmograph was inserted, women were asked to 
slide the positioning shield towards their body until it rested against their vulva. 
3.3.3.1.2. Vaginal lubrication 
Lubrication was measured with the Schirmer Tear Test strips, a test which previous 
research has shown to be sensitive enough to detect changes in vaginal lubrication induced 
by sexual films (Handy & Meston, 2018a). The test strips are ruled in millimeter 
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increments and are 40 millimeters in length. In this assessment, a paper test strip is applied 
directly to the vaginal membrane, and the amount of moisture absorbed into the test strip 
is measured. In an attempt to standardize the depth of insertion of these test strips, they 
were adhered to wooden applicators beginning at five millimeters, thus allowing for only 
the first five millimeters to be inserted into the vaginal opening consistently across 
participants. 
To avoid transference of moisture from the labia to the test strip, women were 
instructed to part their labia with one hand. Using a standing, adjustable mirror as a guide, 
women then inserted the test strip with their free hand until they felt the tip of the wooden 
applicator touch their vaginal skin. This was done to ensure that the test strips were inserted 
at a standardized depth (i.e., five millimeters) and location (i.e., 6 o’clock) for each woman. 
Women held the test strip in place for 60 seconds. At 60 seconds, women were 
instructed to remove the test strip, place it in a plastic bag, and cover up with a drape 
provided by the experimenters. When alerted that the participant is covered, an 
experimenter entered the room to obtain the plastic bag and test strip. Immediately after 
leaving the participant’s room and returning to the experimenter’s room, two experimenters 
independently recorded the length of moisture absorbed into the test strip. To minimize 
potential bias, experimenters running the study sessions were blind to the contraceptive 
method used by the participants. To account for unaroused (i.e., baseline) levels of vaginal 
moisture and capture lubrication that was produced in response to the erotic film, this 
procedure was conducted immediately before and after watching one of the film 
presentations. 
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3.3.3.2. Subjective Arousal 
3.3.3.2.1. Continuous Subjective Sexual Arousal 
Subjective sexual arousal was measured continuously during each film presentation 
with an arousometer (Rellini et al., 2005). The arousometer is a computer mouse attached 
to a lever ranging from 0 to 7, that the participant moves throughout stimuli presentation 
to indicate their perceived level of physiological arousal. The device was positioned on a 
small table at the side of the participant's chair. Each participant began with the lever at 0 
and was instructed to move the mouse to indicate changes in subjective sexual arousal. 
Specifically, they were instructed: “Please move the mouse to indicate any changes in your 
mental sexual arousal, or how turned on you feel in your mind.” The position of the y-axis 
of the mouse was recorded every 0.50 seconds on a computer in the next room using the 
scripting program MatLab 2013b (MathWorks, 2013). The arousometer has been validated 
for use in capturing changes in subjective arousal during exposure to an erotic stimulus 
(Rellini et al., 2005). 
3.3.3.2.2. Discrete Subjective Sexual Arousal 
The majority of laboratory-based studies examining women’s subjective sexual 
arousal ask participants to complete questionnaires at the beginning and end of the film 
presentation. In order to compare the results of the present study to the extant literature, a 
similar measure was administered (Appendix C). The Film Scale (Heiman & Rowland, 
1983) is a 41-item measure that has five subscales: genital arousal, autonomic arousal, 
subjective sexual arousal, negative affect, and positive affect. The Film Scale has been used 
in over 200 sexuality studies since its introduction in 1983, and it is frequently adapted to 
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meet the needs of a given study or laboratory. Though these changes preclude the use of 
reliability or validity statistics, the Film Scale is the measurement of choice for many 
researchers. In the present study, the subjective sexual arousal subscale was used as a 
discrete measure of this construct. 
The subjective sexual arousal subscale, which was used for the discrete 
measurement of this construct, consists of the following three items: “sexual arousal,” 
“mental sexual arousal” and “sexually turned off,” where the latter item is reverse scored. 
Items are rated on a 7-point Likert scale ranging from 1 (not at all) to 7 (intensely). Total 
scores are summed (range: 3 – 21), with greater scores indicated greater levels of subjective 
sexual arousal. 
3.3.3.2.3. Perceived Genital Arousal 
Perceived genital arousal was assessed via five items on the Film Scale (Heiman & 
Rowland, 1983; Appendix C). The perceived genital arousal subscale consists of the items 
genital “warmth,” “wetness/lubrication,” “pulsing/throbbing,” “tenseness/tightness,” and 
“any genital feeling.” Items are rated on a 7-point Likert scale ranging from 1 (not at all) 
to 7 (intensely). Item responses for this subscale are summed (range: 5 - 35), with greater 
scores indicating greater levels of perceived genital arousal. 
3.3.4. Serum Collection 
Participants underwent a small blood draw collected from the cubital vein in the 
supine position. Four milliliters were drawn into serum separating tubes and were then 
stood upright for 30 to 60 minutes to allow for optimal clotting. Samples were centrifuged 
for 15 minutes at 2,200 to 2,500 revolutions per minute. Upon separation, the separated 
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layer of blood serum was aliquoted. In a new plastic transport tube, samples were frozen 
at -80°C until all data were collected and ready for batch analysis performed by Wisconsin 
National Primate Research Center (see Stroud et al., 2007, for an assessment of the stability 
of sex steroid hormones and binding globulins over time). Sex hormone binding globulin 
serum concentrations were measured using commercial enzyme-linked immunosorbent 
assay (ELISA) in nanomoles per liter (nmol/L). This form of assay uses a solid-phase 
enzyme immunoassay to detect the presence of a protein in a sample using antibodies 
directed against that protein. 
3.3.5. Psychological Measures 
3.3.5.1. Demographics 
Demographic characteristics were assessed with a questionnaire on age, age of 
sexual debut, sexual orientation, relationship status, relationship length, medication use, 
race, educational attainment, and household income (Appendix D). These data were used 
to assess for differences between participant groups in an effort to balance these 
background characteristics across groups. 
3.3.5.2. Contraceptive Side Effects 
Women (except for those in the non-hormonal contraceptive control group) were 
provided with an author-constructed list of common side effects of oral contraceptive pills 
and were asked to endorse any symptoms they experienced over the past three months 
(Appendix E). These self-reported data were used to compare both sexual (e.g., changes in 
sexual desire) and nonsexual (e.g., changes in weight) side effects between the two groups. 
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Items are scored in binary, with 1 reflecting the presence of a given symptom and 0 
reflecting the absence. 
3.3.5.3. Sexual Function 
To assess participants’ level of sexual function on a continuous scale, women 
completed the Female Sexual Function Index (FSFI; Rosen et al., 2000), which is a 19-
item self-report questionnaire that assesses the six domains of women’s sexual function 
(desire, arousal, lubrication, orgasm, satisfaction, and pain), as well as overall sexual 
functioning (Appendix F). Total scores range from 1.2 to 36, where poorer sexual function 
is represented by lower scores. The FSFI has been found to have good internal reliability 
(r = 0.89-0.97), test-retest reliabilities (α = 0.79-0.88), and has confirmed discriminant 
validity in distinguishing women with sexual complaints from women without those 
complaints (Rosen et al., 2000; Ryding & Blom, 2015; Wiegel, Meston, & Rosen, 2005). 
Because we anticipated the participation of lesbian and bisexual women in this study, the 
instructions of the FSFI were modified to avoid heterosexual tendencies (i.e., exclusive 
references to penile penetration of the vagina), and were replaced with generic references 
to vaginal penetration. 
3.3.5.4. Sexual Distress 
The Female Sexual Distress Scale-Revised (FSDS-R; DeRogatis, Clayton, Lewis-
D’Agostino, Wunderlich, & Fu, 2008) was used to measure participants’ levels of sexual 
distress. The FSDS-R is a 13-item self-report questionnaire assessing sex-related distress 
(Appendix G). Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 
(always). Total scores on the FSDS-R range from 0 to 52, with higher scores indicating 
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greater distress. The FSDS-R has been shown to have good discriminant validity in 
differentiating between women with and without hypoactive sexual desire disorder, 
satisfactory internal consistency (>0.88 for groups of women with various sexual 
dysfunctions), and test-retest reliability (0.88; Derogatis et al., 2008). 
3.3.5.5. Vulvar and Vaginal Atrophy 
Symptoms of vulvar and vaginal atrophy were assessed with a 5-item measure that 
is commonly implemented in Food and Drug Administration trials assessing vaginal health 
(Appendix H). In this measure, participants rate the severity of the following symptoms on 
a 4-point Likert-type ranging from 0 (mild) to 3 (severe): vaginal dryness, vaginal and/or 
vulvar irritation/itching, dysuria, and vaginal pain associated with sexual activity. 
Participants also dichotomously rate the presence or absence of vaginal bleeding associated 
with sexual activity. 
3.3.5.6. Positive Sexuality Survey 
This author-constructed survey assesses how confident, satisfied, and pleased 
women are with their experience of vaginal lubrication and sexual activity (Appendix I), 
and the scale was developed specifically for the purpose of this dissertation. On this 
measure, participants are instructed to rate the extent to which they agree with the five 
statements on a scale of 1 (strongly disagree) to 6 (strongly agree), where higher scores 
indicate a more positive experience of sexual activity. Participants are also asked to rate 
these questions based on their experiences over the past four weeks. Items are summed, 
and total scores for this measure range from 5 to 30. The Positive Sexuality Survey has yet 
to be validated for use in women, though should still provide researchers with a sense of 
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how confident women are in their sexual arousal responses. The wording and structure of 
this questionnaire were modeled after the FSFI (Rosen et al., 2000). 
3.4. PROCEDURE 
3.4.1. Determining Eligibility 
Interested participants contacted the laboratory and spoke with a trained research 
assistant who provided standardized information regarding the study and answered any 
questions that were raised. Participants were offered the opportunity to complete a 
confidential phone screen to review the inclusion and exclusion criteria. Women who were 
deemed eligible after completing the phone screen were invited to schedule a clinical 
interview and experimental session and were e-mailed a link to the study’s electronic 
Informed Consent Document. 
3.4.2. Clinical Interview 
Participants who agreed to participate in this study and electronically signed the 
Informed Consent Document completed a brief clinical interview either via telephone or 
in-person, based on the participant’s preference. During the interview, women’s level of 
sexual function was assessed to determine the presence or absence of a sexual desire and/or 
arousal dysfunction. Women were then asked about relevant OCP use (e.g., how long they 
had been taking their current OCP, if they had taken different OCPs in the past). The 
screening for sexual dysfunction occurred prior to assessing OCP use in an attempt to 
reduce the possibility of clinician bias. Thus, the clinician was blind to the OCP status of 
the participants while screening for sexual dysfunction. On average, the clinical interview 
was about 30 minutes in duration. 
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3.4.3. Experimental Session 
Individual study sessions were conducted for each participant. Upon arrival to the 
laboratory, participants received an explanation of all study procedures and instruments, 
and they were be allowed the opportunity to ask any questions that they had. Women then 
received a labeled diagram of the vulvar region and detailed instructions on how to perform 
the lubrication measurement, insert the vaginal photoplethysmograph, and attach 
electrocardiogram electrodes. Participants then took part in the first measure of sexual 
arousal. As it is presently unknown whether inserting the vaginal photoplethysmograph 
could interfere with the measure of lubrication, lubrication and VPA were measured in 
response to two separate film presentations. Participants were randomly assigned to the 
order in which their physiological arousal was measured (i.e., lubrication followed by 
VPA, or VPA followed by lubrication). Film order and measure of physiological arousal 
were counterbalanced across participants, and, to minimize the possibility of researcher 
bias, the experimenters were blind to the form of OCP (i.e., androgenic or antiandrogenic, 
if any) used by each participant. 
During the films, participants were instructed to continuously move the 
arousometer to indicate their level of subjective sexual arousal. The two film presentations 
were separated by a 5-minute rest period to allow participants’ arousal to return to baseline. 
During the rest period, women were instructed to read National Geographic’s Inside 
Animal Minds (Keim, 2017) magazine provided by the experimenters. This magazine was 
selected to reduce participants’ exposure to images of people during the rest period, as 
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nonsexual images of people have been shown to increase genital arousal in some instances 
(as reviewed in Lalumière, Sawatsky, Dawson, & Suschinsky, 2020). 
Those who participate in the VPA session prior to the lubrication session were 
asked to gently dry their genitals with a tissue to remove any residual lubrication produced 
from the first film. After completing both measures of sexual arousal, the participants were 
asked to get dressed and complete the final set of demographic and self-report surveys. 
They then underwent a blood draw by a registered nurse or licensed phlebotomist hired by 
Clinical Pathology Laboratories. Upon completion, participants were debriefed and 
compensated with $20.00 (for women recruited through the community) or course credit 
(for women recruited through the Human Subjects Pool) for their time. On average, the 
entire study session lasted about 120 minutes. Refer to Figure 2 for depictions of the two 
counterbalanced conditions to which women were randomized. 
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Figure 2. Participants were randomized to one of these two counterbalanced sessions.   
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3.4.4. Subject Flow 
Recruitment for this study took about 1.25 years (October 2018 through December 
2019). The target sample size for this study was 150 women (50 per group), and it is 
common practice to recruit slightly more than that in case some participants fail to provide 
complete data. With the goal of recruiting 165 women for this study (55 women per group), 
roughly 10 women needed to complete the experimental session per month for the full 1.25 
years. Data collection from previous studies conducted within the Female Sexual 
Psychophysiology laboratory suggested that this pace was ambitious but feasible. I, 
therefore, worked with gynecologists and primary care providers in the local community 
to facilitate participant recruitment. Ultimately, I recruited and ran 130 women through the 
complete study protocol, with 59 women in the control group, 50 women in the androgenic 
group, and 21 women in the antiandrogenic group. 
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CHAPTER 4: DATA ANALYSIS 
4.1. DATA CLEANING AND REDUCTION 
Vaginal pulse amplitude data were exported from AcqKnowledge 3.9.3 (BIOPAC 
Systems, Inc, CA) to Microsoft Excel for processing. Movement artifacts in the data were 
identified and removed by an automatic processing procedure that has been shown to 
effectively remove outliers and provide results that are comparable to visual inspection 
(Pulverman, Meston, & Hixon, 2018). This automatic processing procedure was conducted 
within the R environment (Team, 2019) using the mgcv package for generalized additive 
modeling (Wood, 2011). As described in Pulverman, Hixon, and Meson (2015), the 
procedure calculates the mean and standard deviation of each participant’s heart rate and 
conducts an outlier test on the time between successive beats. The outliers reflect 
movement artifacts in both the heart rate and vaginal pulse amplitude (VPA) data and are 
therefore removed from the data file. 
The remaining, valid heart rate data are used to identify the highest VPA value 
between heart rate peaks (i.e., the VPA peaks). Once the VPA peaks are identified, the 
procedure uses a standard, generalized cross-validated smoothing spline to create a smooth 
trajectory through the VPA data. Using z-scored residuals, probability estimates are 
calculated each data point to determine the presence or absence of movement artifacts 
within the VPA data. Movement artifacts are removed from the data file and the data is 
modeled again. This process continues until all significant artifacts are removed. The 
remaining data were then binned in 5-second epochs representing mean peak-to-peak VPA 
response, yielding a total of 120 data points per participant. 
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The continuously collected subjective sexual arousal data (i.e., via the arousometer) 
were exported from MatLab 2013b (MathWorks, 2013) to Microsoft Excel for processing. 
The subjective sexual arousal data were then binned in 5-second epochs, yielding a total of 
120 data points per film per participant. 
4.2. STATISTICAL ANALYSES 
4.2.1. Test of Potential Confounding Variables 
All study analyses were conducted in R 3.2.3 (Team, 2019). Prior to testing the 
main study hypotheses, possible differences in background characteristics between the 
three participant groups were assessed. As stated above, no demographic variables varied 
significantly between groups and thus were not included in subsequent models as 
covariates (i.e., controlled for by holding constant; see Section 3.2.3.). 
4.2.2. Test of Major Study Hypotheses 
Aim 1: To test for differences in genital blood flow and vaginal lubrication among 
women using oral contraceptive pills with various androgenic properties. 
Aim 1, Part 1: To test for differences in genital blood flow. Using the nlme package 
(Pinheiro, Bates, DebRoy, Sarkar, & Team, 2017) for linear and nonlinear mixed effects, 
growth curve modeling was implemented to examine the extent to which participants’ 
genital blood flow changed over time. If a significant change in blood flow over time 
emerged, group membership (i.e., low-dose ethinylestradiol plus androgenic progestin, 
low-dose ethinylestradiol plus antiandrogenic progestin, and control) was to be entered into 
the equation as a moderator. Growth curve modeling is a modeling technique that conducts 
within-subject analyses of the relationships between predictor and outcome variables and 
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uses the products (i.e., coefficients) as outcome variables for use in between-subject 
analyses. That is, growth curve modeling analyzes data with regards to individual growth. 
This is particularly useful when examining VPA as baseline VPA varies from woman to 
woman, and growth curve modeling allows for each participant to serve as her own control. 
In this study, all equations were modeled with repeated measures. Additionally, the slopes 
and intercepts were entered as random, thus allowing them to vary across participants 
(Baayen, Davidson, & Bates, 2008). A model used to test the relationship between VPA 
and time was based on the following formula: 
Y(VPA)ij = β0 + β1(time)ij + rij 
where Y(VPA)ij is the ith participant’s VPA at the jth time point, allowing for the 
assessment of VPA across participants and time. In this example, β0 is the participant-
specific intercept, β1 is the participant-specific slope, and rij are the residuals. Time is 
treated as a Level 1 (or inter-individual) variable in this model as it varies within and not 
between participants. 
If a significant relationship emerged, an additional analysis was to be conducted to 
determine if group membership moderated this relationship. The mixed model containing 
group membership as a moderator was as follows: 
Y(VPA)ij = β0 + β1(time)ij + β2(group)i + β3(time*group)ij + rij 
where β2(group)i is the categorical demarcation of group membership for the ith participant 
and has three values representing group membership (0 = control; 1 = low-dose 
ethinylestradiol plus androgenic progestin; 2 = low-dose ethinylestradiol plus 
antiandrogenic progestin). In this example, β3(time*group)ij indicates the interaction of 
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group membership and time predicting VPA (i.e., does the effect of time on VPA vary 
among the groups?). In this multilevel model, time was still treated as a Level 1 variable 
and group membership was treated as a Level 2 (or intra-individual) variable, as it does 
not vary within individuals. Rather, group membership reflects differences occurring 
between participants. 
Aim 1, Part 2: To test for differences in lubrication. Initially, a series of paired t-
tests were conducted to determine whether each group experienced increases in lubrication 
from pre- to post-film. Next, a multivariate analysis of variance (MANOVA) was used to 
test for group differences in pre- and post-film levels of lubrication. In the equation, group 
(low-dose ethinylestradiol plus androgenic progestin, low-dose ethinylestradiol plus 
antiandrogenic progestin, and control) was entered as the independent variable, and 
measures of lubrication (pre-film and post-film, separately) were entered as the dependent 
variables. In a MANOVA, the F statistic tests whether the effects (i.e., means of the 
dependent variables) are equal across the groups. A significant F value indicates that there 
are differences in the means of the dependent variables, but it does not indicate where the 
differences lie. Thus, in order to isolate the differences while minimizing the number of 
comparisons (i.e., not running a series of t-tests), a Tukey’s Honest Significant Difference 
(HSD) post-hoc test was performed. Tukey’s HSD balances the need for conservatism in 
alpha adjustment with minimizing the risk for Type II errors (Maxwell, 1980). It is 
considered more conservative than the Least Significant Difference (LSD) test, though less 
conservative than Scheffe’s test (Pizarro, Guerrero, & Galindo, 2002), both of which are 
common post-hoc procedures. 
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Aim 2: To examine the mechanistic role of sex hormone binding globulin in the 
relationship between genital blood flow and lubrication and oral contraceptive use. It was 
planned that, if significant between-group differences were found on measures of 
physiological sexual arousal, mediation analyses would be conducted. Using the mediation 
package for R (Tingley, Yamamoto, Hirose, Keele, & Imai, 2017), serum concentrations 
of sex hormone binding globulin (SHBG) were examined as a mechanism within the 
relationship between the study group and physiological sexual arousal response. In each 
model, group membership was entered as the independent variable, SHBG concentration 
was entered as the mediating variable, and sexual arousal response (VPA or lubrication) 
was entered as the dependent variable. Separate models were run for each dependent 
variable and each between-group comparison (i.e., control versus androgenic, control 
versus antiandrogenic, and androgenic versus antiandrogenic). 
Typical mediation analyses are evaluated based on the relatedness between a series 
of paths, known as the “a,” “b,” and “c” paths (Baron & Kenny, 1986). In this model, the 
“a” path refers to the regression coefficient for the relationship between the independent 
variable and the mediator, the “b” path refers to the coefficient between the mediator and 
the dependent variable, and the “c” path refers to the coefficient between the independent 
and dependent variable through the mediator. R’s mediation package, however, does not 
provide individual path coefficients. Therefore, standardized coefficients for each path 
were calculated using the QuantPsyc package for quantitative psychology tools (Fletcher, 
2012). See Figure 3 for an example path diagram of a standard mediation model. 
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Figure 3. Example mediation model testing sex hormone binding globulin (SHBG) as the mediator between 
group membership (i.e., androgenic, antiandrogenic, or control) and vaginal pulse amplitude (VPA). In this 
Figure, the “a” path reflects the direct path from the independent variable to the mediator, the “b” path reflects 
the direct path from the mediator to the dependent variable, and the “c” path reflects the direct path from the 
independent variable to the dependent variable. In the case of mediation, an additional path, “c’” reflects the 
indirect path from the independent variable to the dependent variable via the mediator. 
Both average causal and average direct mediation were calculated for each model. 
The average causal mediation effect (ACME) represents, for example, the expected 
difference in the potential outcome (e.g., VPA) when the mediator (i.e., SHBG) took the 
value that would realize under the oral contraceptive pill (OCP) group condition (i.e., one 
of the OCP groups) as opposed to the control condition (i.e., the non-hormonal control 
group), while group status itself is held constant. Models used to test the ACME of SHBG 
on physiological sexual arousal response used the following mediational formula: 
δ(t) = E{Y(t, M(t1)) − Y(t, M(t0))} 
where t, t1, t0 reflect the three values of group membership (low-dose ethinylestradiol plus 
antiandrogenic progestin, low-dose ethinylestradiol plus androgenic progestin, and control, 







the potential outcome variable (i.e., sexual response). The average direct effect (ADE) of 
SHBG was calculated as follows: 
ζ(t) = E{Y(t1, M(t)) − Y(t0, M(t))} 
which represents the expected difference in the outcome when the group that is changed 
by the mediator is held constant at the value equal to t. These two quantities, the ACME 
and ADE, were summed to obtain the average total effect of group membership on the 
outcome, τ. See Tingley et al. (2017) for a thorough explanation of mediation calculation. 
Aim 3: To test for differences in measures of subjective sexual arousal among 
women using oral contraceptive pills with various androgenic properties. Two measures 
of subjective sexual arousal were examined in the present study: one continuous measure 
gathered throughout each film presentation, and one discrete measure gathered before and 
after each film presentation. 
Aim 3, Part 1: Continuously measured subjective sexual arousal. Continuously 
measured subjective sexual arousal was examined in an identical fashion to VPA. Using 
the nlme package (Pinheiro et al., 2017) for linear and nonlinear mixed effects, growth 
curve modeling was implemented to examine changes in subjective sexual arousal over 
time. If significant changes in subjective sexual arousal over time emerged, group 
membership (i.e., low-dose ethinylestradiol plus androgenic progestin, low-dose 
ethinylestradiol plus antiandrogenic progestin, and control) was planned to be entered into 
the equation as a moderator. The equations were identical to those presented above for 
VPA, except that the subjective sexual arousal variable took the place of the VPA variable. 
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Aim 3, Part 2: Discretely measured subjective sexual arousal. Similar to the 
analysis described for the measure of lubrication, a MANOVA was used to test for group 
differences in discretely measured subjective sexual arousal at the pre- and post-film level. 
In the equation, group (low-dose ethinylestradiol plus androgenic progestin, low-dose 
ethinylestradiol plus antiandrogenic progestin, and control) was entered as the independent 
variable, and measures of subjective sexual arousal (pre-film and post-film) were entered 
as the dependent variables. As described above, a Tukey’s HSD post-hoc test was 
performed on the resulting MANOVA to isolate the differences while minimizing the 
number of comparisons. 
Aim 4: To test for differences in perceived genital arousal among women using oral 
contraceptive pills with various androgenic properties. As perceived genital arousal was 
measured discretely before and after each film presentation, a MANOVA was similarly 
used to test for group differences in this construct. In the equation, group (low-dose 
ethinylestradiol plus androgenic progestin, low-dose ethinylestradiol plus antiandrogenic 
progestin, and control) was entered as the independent variable, and measures of perceived 
genital arousal (pre- and post-film) were entered as the dependent variables. In agreement 
with the previous discrete analyses, it was planned that a Tukey’s HSD post-hoc test would 
be performed to locate any differences that emerged. 
Aim 5: To explore differences in sexual function among women using oral 
contraceptive pills with various androgenic properties. Two assessments of sexual 
function were examined in the present study: one self-report measure and one clinician-
administered measure. 
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Aim 5, Part 1: To explore for differences in self-reported sexual function among 
women using oral contraceptive pills with various androgenic properties. A MANOVA 
was used to test for differences in self-reported sexual function among the groups of 
women. In this equation, group membership (low-dose ethinylestradiol plus androgenic 
progestin, low-dose ethinylestradiol plus antiandrogenic progestin, and control) was 
entered as the sole independent variable. Each of the six domains of the Female Sexual 
Function Index (FSFI; i.e., desire, arousal, lubrication, orgasm, satisfaction, and pain) were 
entered as dependent variables within the same model. As all domains contribute to the 
calculation of the FSFI total score, a separate ANOVA was conducted on the total score to 
reduce redundancy. A Tukey’s HSD post-hoc test was planned to locate any significant 
differences. 
Aim 5, Part 2: To explore for differences in clinician-assessed sexual function 
among women using oral contraceptive pills with various androgenic properties. A series 
of chi-square tests of independence were conducted to assess for differences in the 
proportion of decreased genital sensations, as well as the presence of diagnosable female 
sexual arousal disorder. The chi-square tests of independence were conducted using the 
MASS package for support functions and datasets for Venables and Ripley’s MASS 
(Ripley et al., 2019). Using the corrplot package for the visualization of correlation 
matrices (Wei & Simko, 2017), analyses of the residuals were conducted to determine the 
location of effects that emerged. 
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4.2.3. Test of Additional Study Measures 
Contraceptive side effects. Women in each of the OCP groups were asked to 
complete a brief survey assessing common contraceptive side effects. Results from this 
measure were entered into a MANOVA model containing group as the sole independent 
variable and each possible side effect as the dependent variables. If significance were to 
emerge, a planned Bonferroni correction for multiple comparisons was to be conducted. 
Sexual distress. Results from the FSDS-R produced one variable reflecting the 
measure’s total score. Thus, an ANOVA was used to examine between-group differences 
in sexual distress. Group membership (low-dose ethinylestradiol plus androgenic 
progestin, low-dose ethinylestradiol plus antiandrogenic progestin, and control) was 
entered into the equation as the sole independent variable, and sexual distress total score 
was entered into the equation as the sole dependent variable. 
Vulvovaginal atrophy. The Vulvovaginal Atrophy Assessment contained both 
dichotomously scored and Likert-style items. Therefore, the dichotomously scored item 
was assessed with a chi-square test of independence. The chi-square test of independence 
was conducted using the MASS package for support functions and datasets for Venables 
and Ripley’s MASS (Ripley et al., 2019). The remaining four items were entered into a 
MANOVA to assess group differences. Similar to the assessment of sexual function, a 
separate ANOVA was conducted on the measure’s total score to reduce redundancy within 
the MANOVA model. 
Positive sexuality. As with the measure of sexual distress, results from the author-
constructed assessment the Positive Sexuality Survey produced one variable reflecting the 
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measure’s total score. An ANOVA was therefore used to examine between-group 
differences in positive sexuality. Group membership was entered into the equation as the 
sole independent variable, and the measure’s total score was entered into the equation as 
the sole dependent variable. 
4.2.4. Statistical Power Considerations 
Statistical power is the likelihood of rejecting the null hypothesis (e.g., determining 
that there are significant group differences) when the null hypothesis is false (e.g., when 
there truly are significant group differences). Repeated measures designs are virtually 
always more powerful than designs in which measurements are only collected at one time 
(Murphy, Myors, & Wolach, 2014) as the increase in time points allows for increased 
reliability of the data. Given the sheer quantity of time points gathered through the time-
series data collection methods in the present study, these equations are likely the most 
powerful of the conducted analyses. Therefore, growth curve modeling analyses were not 
considered when calculating statistical power. 
 A power analysis for a multivariate ANOVA with three groups and a low (r = 0.25) 
correlation between time points indicated that a total sample of N = 123 would be required. 
This would allow for 90% power to detect a true effect with an α of 0.05 (two-tailed) and 
a small effect (f = .2). The a priori effect size of .2 was selected as a conservative effort; 
smaller effect sizes require a larger sample size to be detected, whereas larger effect sizes 
require a smaller sample size. Thus, with a final sample size of 130 women, the study as a 
whole was sufficiently powered to detect a true small effect. 
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4.2.5. Procedure for Missing Data 
 For between-group comparisons, participants with data missing from only the 
measures in question were excluded. For example, if a participant was missing data on 
perceived genital arousal, her data were excluded from the model involving perceived 
genital arousal only, but not the other models for which she did have present and viable 
data. The computer system for self-report data required women to select an answer for 
every item, even if they selected “Skip,” therefore minimal data were missing in this study. 
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CHAPTER 5: RESULTS 
5.1. FINDINGS OF THE MAJOR STUDY HYPOTHESES 
5.1.1. Validity Check for Order Effects of Video Manipulation 
Women were randomly assigned to the order in which their physiological sexual 
arousal was measured (i.e., blood flow followed by lubrication, or lubrication followed by 
blood flow). As such, assessments of potential order effects were conducted. Linear mixed 
effects models including sexual arousal measurement as the dependent variable and 
measurement order as the independent variable found no significant order effects for 
women’s vaginal pulse amplitude (VPA), t(125) = 0.388, p = .698, nor subjective sexual 
arousal, t(125) = 0.617, p = .538, responses. Results from a multivariate analysis of 
variance (MANOVA) found no differences in the order in which lubrication was measured, 
F(1, 127) = 1.911, p = .152. 
Similarly, subjective sexual arousal and perceived genital arousal were measured 
in response to both sexual films. Thus, to assess for possible carry-over effects, differences 
on these measures between the two films were assessed. No significant differences on pre- 
nor post-film levels of perceived genital arousal, t(129) = 0.989, p = .201 and t(129) = -
1.308, p = .193, respectively, and perceived autonomic arousal, t(129) = 0.895, p = .371 
and t(129) = 0.478, p = .633, respectively, were found between the two films. These results 
suggest there was no measured effect of the first film on physiological and self-report 
measures gathered during the second film. Given this lack of differences, measurement 
order was not controlled for in subsequent analyses containing any of these variables. 
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5.1.2. Group Variations in Vaginal Blood Flow 
Significant increases in VPA over the course of the sexual films were depicted in 
all three groups of women. In line with the study hypothesis, naturally-cycling women 
exhibited the strongest VPA response (b0 = 26.01 millivolts; mV), with a notably greater 
baseline level of VPA compared to the two groups of women taking oral contraceptive pills 
(OCPs). This was followed by women taking androgenic OCPs (b0 = 20.80 mV) and then 
women taking antiandrogenic OCPs (b0 = 14.67 mV), who displayed the weakest VPA 
response. See Figure 4 for a visualization of the VPA responses for each group. 
 
Figure 4. Linear slopes indicating average change in vaginal blood flow over the course of an erotic film for 
women in the control, androgenic, and antiandrogenic groups. In this Figure, vaginal pulse amplitude is 
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measured in millivolts, indicated as “mV.” Women in the control group (i.e., not taking oral contraceptive 
pills) exhibited a significantly greater response than did women in androgenic or antiandrogenic group. For 
clarity, this Figure displays unstandardized effects. 
As can be seen in Figure 4, women taking androgenic OCPs also displayed the 
steepest slope in VPA, with an average increase of 0.036 mV/5 seconds, which equates to 
0.432 mV/minute, t(5830) = 44.33, p < .001. This effect was followed by women in the 
control group, who had an average increase of 0.030 mV/5 seconds, or 0.36 mV/minute, 
t(6782) = 34.01, p < .001. Lastly, in addition to exhibiting the weakest overall VPA 
response, women taking antiandrogenic OCPs also displayed the flattest slope, with an 
average increase of 0.022 mV/5 seconds, or 0.264 mV/minute, t(2498) = 29.24, p < .001. 
A moderated hierarchical linear regression found significant effects of study group 
on the slope of the VPA line for women in the androgenic and antiandrogenic groups. As 
the temporal nature of VPA would indicate, this effect was only significant when 
examining change in VPA over time; estimates that did not include time within the model 
were not significant. This suggests that the VPA responses for women in both of these 
groups were significantly different from, and, in this case, significantly lower than, the 
responses of women in the control group. This effect was most pronounced in women 
taking antiandrogenic OCPs. These results suggest the presence of a slight inhibitory effect 
of androgenic OCPs and a marked inhibitory effect of antiandrogenic OCPs on vaginal 





Moderated Hierarchical Regression Estimates for Vaginal Pulse Amplitude as 
Predicted by Time (Level 1) and Oral Contraceptive Pill Group (Level 2) 
Variable Value SE df t p 
Intercept 26.018 3.102 15110 8.387 .0000 
Time 0.030 0.001 15110 38.355 .0000 
Androgenic -5.212 4.562 124 -1.142 .2554 
Antiandrogenic -11.343 5.978 124 -1.897 .0601 
Time x Androgenic 0.006 0.001 15110 5.792 .0000 
Time x Antiandrogenic -0.007 0.001 15110 -5.025 .0000 
 
Note: SE = standard error; df = degrees of freedom. Estimates for each Level 2 analysis reflect results for 
the stated group against the control group. Women in the control group exhibited significantly greater 
vaginal pulse amplitude responses than did women in either of the oral contraceptive pill groups. 
5.1.3. Group Variations in Vaginal Lubrication 
Significant increases in vaginal lubrication from pre- to post-film were 
demonstrated in each of the three study groups. On average, women in the non-hormonal 
control group experienced a 5.28 mm (SD = 5.63) increase in lubrication from pre- to post-
film, t(58) = 7.185, p < .0001. Women taking androgenic OCPs exhibited a lesser 
lubrication response, with an average increase of 3.89 mm (SD = 4.07) of lubrication, t(49) 
= 6.754, p < .0001). Finally, women taking antiandrogenic OCPs exhibited an average 
increase of 4.16 mm (SD = 3.03) of vaginal lubrication, t(20) = 6.292, p = .000003). Results 
of a MANOVA identified significant differences in lubrication scores among the three 
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groups of women, F(2, 254) = 2.254, p = .063. See Figure 5 for a visualization of pre- and 
post-film levels of lubrication for the three study groups. 
 
Figure 5. Average pre- and post-film measures of lubrication for women in the control, androgenic, and 
antiandrogenic groups. In this Figure, lubrication is measured in millimeters, indicated as “mm.” Pre-film 
measures are indicated as Time “1,” and post-film measures are indicated as Time “2.” Error bars represent 
upper and lower percentiles. Women taking antiandrogenic oral contraceptive pills exhibited significantly 
weaker baseline lubrication compared to women in the other two groups, whereas those in the control group 
exhibited a significantly stronger lubrication response post-film compared to women in the other two groups. 
In the event that significant differences were to emerge, it was planned that Tukey’s 
Honest Significant Difference post-hoc analyses would be conducted to identify the 
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location(s) of the significant effect(s). These post-hoc analyses revealed significantly lower 
levels of baseline (i.e., pre-film, unaroused) lubrication in women taking antiandrogenic 
OCPs compared to women in the control group (p = .060), as well as significantly lower 
levels of post-film lubrication (i.e., aroused) in women taking androgenic (p = .064) and 
antiandrogenic (p = .045) OCPs compared to those in the control group. These results 
mimic the previously reported variations in VPA, suggesting that type of OCP influences 
physiological sexual arousal in women. This appears to be particularly true for 
antiandrogenic OCPs.  
5.1.4. Mediating Effect of Sex Hormone Binding Globulin 
Prior to examining the potential mediating effect of sex hormone binding globulin 
(SHBG) on physiological sexual arousal, between-group differences were assessed. Had 
no between-group differences emerged, mediation would not be conducted. The study’s 
design of random sampling for participation in the blood draw yielded 87 total samples: 37 
from women in the control group, 35 from women in the androgenic group, and 15 from 
women in the antiandrogenic group. Results from an ANOVA indicated significant 
differences in serum SHBG concentrations across the three study groups, F(2) = 85.50, p 
< .0001. Planned post-hoc analyses conducted to identify the location(s) of the significant 
difference(s) found all three comparisons to be significant (i.e., control versus androgenic, 
control versus antiandrogenic, and androgenic versus control; ps < .0001). As expected, 
serum SHBG concentrations were lowest in women in the control group (M = 54.76, SD = 
26.19), followed by the androgenic group (M = 109.99, SD = 45.82), and finally the 
antiandrogenic group (M = 253.01, SD = 88.64). See Figure 6 for plotted results. 
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Figure 6. Average and actual serum sex hormone binding globulin (“SHBG”) levels for women in each 
group. Here, SHBG is measured in nanomoles per liter (nmol/L). Control, androgenic, and antiandrogenic 
groups are noted as 0, 1, and 2, respectively, with significant between-group differences for each comparison. 
5.2.4.1. Findings for Vaginal Blood Flow 
The relationship between OCP group and VPA was partially, but not meaningfully, 
mediated by the serum concentrations of SHBG. As Figure 7 illustrates, for women taking 
androgenic OCPs compared to women in the control group, the standardized regression 
coefficient between study group and SHBG was statistically significant, with an average 
direct effect (ADE) of .640, p < .0001. The standardized regression coefficient between 
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SHBG and VPA was also significant, ADE = -.054, p < .0001, as was the indirect effect of 
study group on VPA, r = -.086, p < .0001, indicating a related series of effects.  
 
Figure 7. Model reflecting the effect of study group on vaginal pulse amplitude (VPA), as mediated by sex 
hormone binding globulin (SHBG) for women in the androgenic and control groups. Significant direct and 
indirect effects indicate that group influences SHBG, which, in turn, influences VPA, though this series of 
effects was not significant through mediation. 
The significance of the entire model was tested using quasi-Bayesian procedures. 
Unstandardized indirect effects were computed for 1,000 simulated samples; the 95% 
confidence interval was computed by determining the indirect effects at the 2.5th and 97.5th 
percentiles. The simulated unstandardized indirect effect was -3.924 and the 95% 
confidence interval ranged from -4.922 to -2.89 and was statistically significant, p < .0001. 
Further investigation of the model revealed that this was driven by the direct effect of study 
group on VPA; the product of the a and b paths was not significant. The average causal 
mediation effect (ACME) was also not significant (ACME = 0.054 [-0.746, 0.870], p = 
.900), with a proportional mediation of -0.01. 
A similar pattern emerged for women taking antiandrogenic OCPs compared to 








path between group and SHBG was statistically significant, ADE = .873, p < .0001, as was 
the standardized coefficient for the path between SHBG and VPA, ADE = -.277, p < .0001. 
The indirect effect of study group on VPA was also significant, r = -.310, p < .0001. The 
simulated unstandardized indirect effect was -15.765, and the 95% confidence interval 
ranged from -16.965 to -14.550 and was statistically significant, p < .0001. Investigation 
of the model revealed that this was similarly driven by the direct effect of group on VPA; 
the product of the a and b paths was not significant (ACME = -1.133 [-3.225, 1.130], p = 
.290), with a proportional mediation of 0.07. See Figure 8 for a path model of these effects. 
 
Figure 8. Model reflecting the effect of study group on vaginal pulse amplitude (VPA), as mediated by sex 
hormone binding globulin (SHBG) for women in the antiandrogenic and control groups. Significant direct 
and indirect effects indicate that group influences SHBG, which, in turn, influences VPA, though this series 
of effects was not significant through mediation. 
Finally, as indicated in Figure 9, partial, but not meaningful, mediation occurred 
when comparing women taking androgenic OCPs against women taking antiandrogenic 
OCPs. Similar to the other two models, significant effects emerged for the direct path 
between study group on SHBG (ADE = .734, p < .0001), the direct path between SHBG 








= -262, p < .0001). The simulated unstandardized indirect effect was -11.764, and the 95% 
confidence interval ranged from -12.845 to -10.700 and was statistically significant, p < 
.0001. The product of the a and b paths was not significant (ACME = -0.241 [-1.370, 
0.097], p = .068) and had a proportional mediation of 0.02; the significance of the model 
was again driven by the indirect effect. Taken together, this series of results indicate that 
differences in SHBG concentration influence, but do not fully explain, the observed 
between-group differences in VPA. 
 
Figure 9. Model reflecting the effect of study group on vaginal pulse amplitude (VPA), as mediated by sex 
hormone binding globulin (SHBG) for women in the androgenic and antiandrogenic groups. Significant 
direct and indirect effects indicate that group influences SHBG, which, in turn, influences VPA, though this 
series of effects was not significant through mediation. 
5.2.4.2. Findings for Vaginal Lubrication 
Post-film measures of lubrication were used in the following mediation models. 
This was selected as opposed to pre-film measures or difference scores (i.e., change from 
pre- to post-film). As women’s pre- and post-film measures of lubrication differed, 
variations in lubrication difference scores may have been masked during analyses. For 








pre- and post-film lubrication and one with above-average levels may not appear different 
from each other, despite the first participant achieving a lower overall level of lubrication. 
This lower level of overall lubrication may be clinically meaningful and should not be 
overlooked. Thus, post-film measures of lubrication were selected as the index of choice 
for the subsequent analyses in hopes of capturing meaningful between-group differences. 
As depicted in Figure 10, no significant mediation occurred in women taking 
androgenic OCPs compared to women in the control group. There was a significant direct 
effect of group on SHBG, ADE = .602, p < .0001, though the effect of SHBG on lubrication 
was not significant, ADE = -.188, p = .113. The indirect effect of group on lubrication was 
significant, however, so the mediation model was continued, r = -.289, p = .014. Using 
quasi-Bayesian procedures, the significance of the model was estimated through the 
computation of 1,000 simulated samples. The simulated unstandardized indirect effect was 
-3.8377, and the 95% confidence interval ranged from -7.007 to -0.61 and was statistically 
significant, p = 0.018. The causal mediation, however, was not, ACME = -0.172 [-2.5479, 
2.100], p = 0.898, and the model had a proportional mediation of .03. 
 
Figure 10. Model reflecting the effect of study group on post-film levels of lubrication, as mediated by sex 
hormone binding globulin (SHBG) for women in the androgenic and control groups. The significant direct 
SHBG 





between group and SHBG indicates that SHBG varied significantly across group, and the significant indirect 
effect from group to post-film lubrication suggests indicates that lubrication also varied significantly across 
group. The role of SHBG in this indirect relationship, however, does not appear to be sufficient for mediation. 
Similar patterns were found for women taking antiandrogenic OCPs compared to 
women in the control group. In this model, the standardized regression coefficient for the 
direct path between study group and SHBG was statistically significant, ADE = .870, p < 
.0001, though the standardized coefficient for the direct path between SHBG and 
lubrication was not significant, ADE = -0.175, p = .213. There was a significant indirect 
effect of group on lubrication, r = -.268, p = .054. The simulated unstandardized total effect 
was -3.947 with a 95% confidence interval that ranged from -7.945 to -0.03 and was 
statistically significant, p = 0.050. However, the causal mediation depicted by the model 
indicated no significant mediation effects of SHBG on the relationship between study 
group and lubrication, ACME = 2.818 [-3.850, 10.130], p = 0.444. Proportional mediation 
for this model was -.70. See Figure 11 for a path diagram highlighting these results. 
 
Figure 11. Model reflecting the effect of study group on post-film levels of lubrication, as mediated by sex 
hormone binding globulin (SHBG) for women in the antiandrogenic and control groups. The significant 
direct between group and SHBG indicates that SHBG varied significantly across group, and the significant 
SHBG 





indirect effect from group to post-film lubrication suggests indicates that lubrication also varied significantly 
across group. The role of SHBG in this indirect relationship, however, does not appear to be sufficient for 
mediation. 
A slightly different pattern of results emerged for women in the androgenic 
compared to antiandrogenic groups. For these women, there was a significant direct effect 
of study group on SHBG, ADE = 0.736, p < .0001, and no significant direct effect of SHBG 
on post-film levels of lubrication, ADE = 0.025, p = .859. However, the indirect effect of 
group on lubrication was also nonsignificant, with an r of -.008, p = .954. The simulated 
model confirmed these results, indicating a total effect of -0.087, with a 95% confidence 
interval that ranged from -3.427 to 3.35   p = 0.96. Similarly, the causal mediation was also 
nonsignificant, ACME = 0.521 [-2.903, 4.35], p = 0.81. Proportional mediation for this 
model was -.04. See Figure 12. Taken together, this series of results indicate that, whereas 
SHBG concentration varies by women’s hormonal profile, it may not play a large enough 
role in variations in lubrication to be evident within a mediation model of this nature. 
 
Figure 12. Model reflecting the effect of study group on post-film levels of lubrication, as mediated by sex 
hormone binding globulin (SHBG) for women in the androgenic and antiandrogenic groups. The only 
significant path that emerged within this model was the direct path from study group to SHBG, indicating 
that SHBG levels varied significantly by group, but this does not appear to play a role in post-film lubrication. 
SHBG 





5.1.5. Group Variations in Subjective Sexual Arousal 
5.1.5.1. Findings for Continuous Subjective Sexual Arousal 
As no significant differences were found between subjective sexual arousal 
measured during the first and second film sessions for either group, for simplicity, only 
subjective sexual arousal responses that were captured during the first film were included 
in the following analyses. Significant increases in subjective sexual arousal over the course 
of the films were depicted in all three groups of women. Women in the control group 
exhibited the flattest slope and, ultimately, achieved the lowest level of subjective sexual 
arousal at the end of the film. They displayed an average increase of 0.00104 units/5 
seconds, which equates to 0.012 units/minute, t(6782) = 87.88, p < .001.  
On the other hand, women in the androgenic and antiandrogenic groups exhibited 
remarkably similar slopes for their subjective sexual arousal responses. For both groups of 
women taking OCPs, subjective sexual arousal responses were significantly greater than 
those of women in the control group. Women in these two groups also exhibited steeper 
slopes of their subjective sexual arousal lines, which reflects more rapid change in this 
measure. Women in the androgenic group experienced an average increase of 0.001 mV/5 
seconds, or 0.014 mV/minute, t(5830) = 88.96, p < .001, and women taking antiandrogenic 
OCPs displayed an average increase of 0.00128 mV/5 seconds, which translates to 
increases of 0.015 mV/minute, t(2498) = 61.65, p < .001. See Figure 13 for a graphical 
depiction of the subjective sexual arousal slopes for each study group. 
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Figure 13. Linear slopes indicating average change in subjective sexual arousal over the course of an erotic 
film for women in the control, androgenic, and antiandrogenic groups. Women in the androgenic and 
antiandrogenic groups exhibited significantly greater subjective sexual arousal responses compared to 
women in the control group. For ease of interpretation, this Figure depicts unstandardized modeled effects. 
A moderated hierarchical linear regression found significant effects of the study 
group on the slope of the subjective sexual arousal line over time for both of the OCP 
groups. According to this model, there were significantly greater subjective sexual arousal 
responses in women taking androgenic and antiandrogenic OCPs compared to women in 
the control group. Women in the control group displayed the lowest level of subjective 
sexual arousal throughout the film. In contrast to the study’s hypothesis, these results 
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suggest a possible enhancing effect of OCPs on women’s experience of subjective sexual 
arousal in response to erotic stimuli. See Table 6 for the complete model output. 
Table 6. 
Moderated Hierarchical Regression Estimates for Subjective Sexual Arousal as 
Predicted by Time (Level 1) and Oral Contraceptive Pill Group (Level 2) 
Variable Value SE df t p 
Intercept -0.068 0.025 15110 -2.725 .006 
Time 0.001 0.00001 15110 84.800 .0001 
Androgenic 0.025 0.036 124 0.698 .486 
Antiandrogenic -0.031 0.048 124 -0.641 .522 
Time x Androgenic 0.0001 0.00001 15110 9.445 .0001 
Time x Antiandrogenic 0.0002 0.00002 15110 10.056 .0001 
 
Note: SE = standard error; df = degrees of freedom. Estimates for each Level 2 analysis reflect results for 
the stated group against the control group. Women in the androgenic and antiandrogenic oral contraceptive 
pill groups exhibited significantly greater degrees of subjective sexual arousal than did women in the 
control group. 
5.1.5.2. Findings for Discrete Subjective Sexual Arousal 
As no significant differences were found between subjective sexual arousal 
measured with respect to the first and second film sessions, only subjective sexual arousal 
data for the first film were used in the following analyses. A MANOVA examining 
differences in pre- and post-film levels of discretely measured subjective sexual arousal 
among the three study groups revealed no significant differences, F(2, 254) = 1.075, p = 
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.369. On average, scores for women in the control group increased from 5.64 (SD = 2.31) 
to 9.11 (SD = 2.95). Scores for women in the androgenic group similarly increased from 
5.28 (SD = 2.26) to 8.98 (SD = 2.66), and, similarly, those for women in the antiandrogenic 
group increased from 4.61 (SD = 1.88) to 9.47 (SD = 2.15). These results suggest that any 
between-group differences in subjective sexual arousal are best detected when examining 
continuous changes in this construct throughout stimulus exposure; it appears as though it 
is important to take into consideration the temporal nature of subjective sexual arousal 
when comparing responses from these groups of women. See Tables 7 and 8 for pre- and 





Item-Level Analyses for Pre-Film Mental Sexual Arousal Across the Study Groups 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21 
Arousal item M SD M SD M SD 
Sexually aroused 1.42 0.79 1.30 0.70 1.14 0.65 
Mental sexual arousal 1.44 0.85 1.50 0.90 1.14 0.35 
Sexually turned off 2.77 2.15 2.48 1.96 2.33 1.65 
 
Note: M = mean; SD = standard deviation. Scores for the item “Sexually turned off” have been reverse 
scored. No significant between-group differences were identified. 
 96 
5.1.6. Group Variations in Perceived Genital Arousal 
Ratings of perceived genital arousal were not significantly different between the 
first and second films; therefore, all reported results reflect ratings gathered in relation to 
the first film session. A MANOVA model revealed no significant between-group 
differences on pre-film levels of perceived genital arousal, F(2, 246) = 0.606, p = .836. 
This lack of difference was expected and likely due to a general floor effect. In other words, 
pre-film measures of this construct were expected be minimal as arousal had yet to be 
induced, thus there were minimal to no genital arousal sensations to be perceived. 
Significant increases on this domain were noted for each group, however, with ts ranging 
from |7.898| to |9.428|. These values indicate relatively large changes in perceived genital 
arousal from pre- to post-film for each study group. See Table 9 for pre-film item-level raw 
scores for each study group. 
 
Table 8. 
Item-Level Analyses for Post-Film Mental Sexual Arousal Across the Study Groups 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21 
Arousal item M SD M SD M SD 
Sexually aroused 3.84 1.66 3.78 1.21 4.09 1.37 
Mental sexual arousal 3.55 1.71 3.74 1.42 3.85 1.45 
Sexually turned off 1.71 1.26 1.46 0.70 1.52 0.81 
 
Note: M = mean; SD = standard deviation. Scores for the item “Sexually turned off” have been reverse 
scored. No significant between-group differences were identified. 
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Despite the significant increases from pre- to post-film for each study group, no 
significant between-group differences were found for post-film ratings of perceived genital 
arousal, F(2, 246) = 0.823, p = .626. Contrary to the study hypothesis that ratings of 
perceived genital arousal would mimic the observed patterns of physiological measures of 
arousal, no hormone-related variations were detected. Indeed, these results suggest that 
OCP use does not appear to influence women’s perceptions of their genital sexual arousal, 
despite the presence of physiological deficits. See Table 10 for post-film item-level raw 




Item-Level Analyses for Pre-Film Genital Arousal Across the Study Groups 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21 
Arousal item M SD M SD M SD 
Warmth 1.96 1.12 1.72 1.03 1.47 0.60 
Wetness/lubrication 1.88 1.06 1.82 1.06 1.57 0.59 
Pulsing/throbbing 1.16 0.62 1.16 0.42 1.23 0.53 
Tenseness/tightness 1.55 1.00 1.48 0.93 1.47 0.98 
Any genital feeling 1.88 1.05 1.88 0.93 1.71 0.84 
Total score 8.45 3.87 8.06 3.47 7.47 2.56 
 
Note: M = mean; SD = standard deviation. To avoid redundancy, the total score of this subscale was 
not included in the MANOVA model. No significant between-group differences were identified. 
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Table 10. 
Item-Level Analyses for Post-Film Genital Arousal Across the Study Groups 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21 
Arousal variable M SD M SD M SD 
    Warmth 3.27 1.41 3.36 1.54 3.28 1.48 
    Wetness/lubrication 3.77 1.56 3.74 1.29 3.61 1.43 
    Pulsing/throbbing 2.89 1.79 3.22 1.65 3.00 1.76 
    Tenseness/tightness 2.49 1.47 2.82 1.58 2.76 1.81 
    Any genital feeling 3.91 1.50 4.04 1.51 4.23 1.54 
    Total score 16.35 6.45 17.18 6.17 16.90 6.70 
 
Note: M = mean; SD = standard deviation. To avoid redundancy, the total score of this subscale was 
not included in the MANOVA model. No significant between-group differences were identified for this 
measure. 
5.1.7. Group Variations in Sexual Function 
5.1.7.1. Self-Reported Sexual Function 
Results from a MANOVA indicated no significant between-group differences 
emerged for any domain of sexual functioning, F(2, 246) = 1.501, p = .123. An ANOVA 
confirmed there were no significant differences in overall sexual function, F(2) = 0.369, p 
= .692. On average, women’s total score on the Female Sexual Function Index (FSFI) was 
27.00 (SD = 5.88), which is slightly greater than the cutoff (26.55) score for sexual 
dysfunction (Wiegel et al., 2005). Though this indicates a relatively low level of sexual 
function for women who do not have sexual dysfunction, such scores are not abnormal for 
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women of this age (Meyer-Bahlburg & Dolezal, 2007), and are driven, in part, by lower 
scores on the Orgasm domain. In the present study, scores on the Orgasm domain were 
nearly one point lower than scores on the other domains (3.74 versus 4.65, respectively). 
See Table 11 for group-level domain and total scores for the FSFI. 
Table 11. 
Female Sexual Function Index Domain and Total Scores for Each Study Group 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21 
FSFI Domain M SD M SD M SD 
Desire 4.14 0.89 4.33 0.91 4.11 0.83 
Arousal 4.73 1.11 4.65 1.21 4.88 0.88 
Lubrication 4.93 1.41 5.03 1.21 4.71 1.06 
Orgasm 3.74 1.74 3.59 1.69 4.13 1.18 
Satisfaction 4.51 1.62 4.34 1.45 5.12 0.86 
Pain 4.87 1.66 4.67 1.41 4.97 1.39 
Total score 26.99 6.63 26.62 5.74 27.94 3.64 
 
Note: FSFI = Female Sexual Function Index; M = mean; SD = standard deviation. No significant 
between-group differences emerged on any of the six domains of sexual function nor overall 
sexual function (as depicted by the measure’s total score). 
5.1.7.2. Clinician-Assessed Sexual Function 
In contrast to self-reported sexual function, notable between-group differences in 
sexual arousal function emerged during the clinical interview. Female sexual arousal 
disorder was identified in seven (33.33%) of women taking antiandrogenic OCPs, 12 
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(24.00%) of women taking androgenic OCPs, and five (8.47%) of women in the control 
group. As later described, these results were driven, primarily, by decrements in vaginal 
lubrication. A chi-square test of independence indicated a significant relationship between 
study group and the presence of female sexual arousal disorder, χ2(2) = 8.013, p = .018. An 
analysis of the residuals of the chi-square test indicated that women in the antiandrogenic 
group were significantly more likely, and those in the control group were significantly less 
likely, to meet the criteria for female sexual arousal disorder. Despite the increased 
prevalence in women taking androgenic OCPs compared to women in the control group 
(i.e., 24.00% versus 8.47%), this difference did not reach statistical significance. 
As a part of the clinical interview for female sexual arousal disorder, changes in 
(i.e., increases, no changes, decreases, or absence of) five prominent components of genital 
sexual arousal were assessed. Whereas no differences were found for pleasurable sexual 
feelings, pulsing/throbbing, fullness/pressure/engorgement, and genital warmth, women in 
the antiandrogenic group more often reported decreased or absent experiences of genital 
lubrication compared to women in the control group. A similar pattern emerged for women 
in the androgenic group, though this difference was not significant; rates of decreased or 
absent lubrication were twice as high for women in the antiandrogenic compared to the 
androgenic group. It, therefore, appears as though women taking antiandrogenic OCPs are 
most impacted by female sexual arousal disorder compared to women taking androgenic 
OCPs or those who are naturally-cycling. Refer to Table 12 for summary statistics of the 
frequency with which women in each group endorsed decrements in the five sexual arousal 
sensations used to screen for female sexual arousal disorder. 
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Table 12. 
Number of Women Reporting Decreased or Absent Sexual Arousal Sensations by Group 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21  
Genital sensation n % n % n % χ2 
Pleasurable sexual 
feelings 5 8.47 9 18.00 4 19.04 2.626 
Pulsing or throbbing 13 26.00 6 14.63 5 33.33 3.755 
Fullness, pressure, or 
engorgement 6 20.68 8 26.66 2 16.66 0.586 
Warmth 5 10.41 2 5.26 4 2.83 7.737 
Wetness or lubrication 5 8.47 14 28.57 13 61.90 24.555*** 
 
Note: A significantly greater frequency of women taking antiandrogenic oral contraceptive pulls reported 
decreased or absent lubrication compared to women in the control group. A significantly greater proportion 
of women in the antiandrogenic group reported decreased or absent vaginal wetness or lubrication compared 
to women in either of the other two groups. 
*** p = .00006 
5.2. ADDITIONAL STUDY MEASURES 
5.2.1. Contraceptive Side Effects 
Women in the control group (i.e., not using OCPs) were excluded from this 
analysis. Two reduce redundancy of testing and likelihood of detecting false positives, all 
25 assessed contraceptive side effects were entered into the same MANOVA model. 
Results from this model indicated no significant differences between the two OCP groups 
on any item, F(1, 25) = 1.394, p = .163. The most common side effects reported by women 
taking androgenic OCPs included, in order, lighter menstrual periods, fewer or weaker 
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menstrual cramps, decreases in mood, intermenstrual spotting, and vaginal discharge. The 
most common side effects reported by women taking antiandrogenic OCPs, in order, 
included lighter menstrual periods, fewer or weaker menstrual cramps, decreases in mood, 
decreases in acne, and bloating. It is of note that one-quarter of women taking androgenic 
OCPs reported increases in sexual desire, whereas one-third of women taking 
antiandrogenic OCPs reported decreases in sexual desire. The percentage of women 
endorsing vaginal dryness was also twice as high for women taking antiandrogenic OCPs 
compared to those taking androgenic OCPs (33.33% versus 16.00%, respectively). Refer 
to Table 13 for a list of possible side effects and frequency of endorsement by the two 
groups of women. 
Table 13. 
Frequency of Side Effects Endorsed by Women Taking Oral Contraceptive Pills 
 Androgenic N = 50 
Antiandrogenic 
N = 21 
Contraceptive side effect n % n % 
Intermenstrual spotting 20 40.00 3 14.28 
Lighter menstrual periods 38 76.00 14 66.66 
Heavier menstrual periods 1 2.00 2 9.52 
Missed periods 14 28.00 2 9.52 
Fewer or weaker menstrual cramps 25 50.00 13 61.90 
More or stronger menstrual cramps 6 12.00 1 4.76 
Blood clots 3 6.00 1 4.76 
Nausea 6 12.00 3 14.28 
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Table 13 (continued). 
Bloating 15 30.00 9 42.85 
Weight gain 11 22.00 4 19.04 
Weight loss 1 2.00 0 0 
Increased appetite 12 24.00 4 19.04 
Decreased appetite 1 2.00 3 14.28 
Decreases in mood 23 46.00 10 47.61 
Improvements in mood 5 10.00 4 19.04 
Headaches or migraines 6 12.00 6 28.57 
Blurred vision 0 0 1 4.76 
Increased acne 6 12.00 2 9.52 
Decreased acne 15 30.00 10 47.61 
Breast tenderness 10 20.00 7 33.33 
Decreased libido 9 18.00 7 33.33 
Increased libido 12 24.00 4 19.04 
Vaginal discharge 16 32.00 5 23.80 
Vaginal dryness 8 16.00 7 33.33 
Other 1 2.00 1 4.76 
 
Note: Women were instructed to endorse as many side effects as they experienced. Therefore, the total 
number reported is not equivalent to the total number of women in each of the two study groups. Only 
women taking oral contraceptive pills completed this measure. No significant between-group differences 
in contraceptive side effects emerged. 
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5.2.2. Group Variations in Sexual Distress 
The average score on the Female Sexual Distress Scale-Revised for all groups was 
8.26 (SD = 8.99), which is below the cutoff (11.00) for clinically meaningful distress 
(DeRogatis et al., 2008). This indicates that, on average, women who participated in this 
study did not experience clinical levels of sexual distress. Overall, the three groups of 
women reported similar levels of sexual distress: women taking androgenic OCPs reported 
the greatest level of sexual distress (M = 8.54, SD = 8.68), followed by women in the 
control group (M = 8.28, SD = 9.39), and then women in the antiandrogenic group (M = 
7.52, SD = 8.99). An ANOVA found no between-group difference in sexual distress, F(2) 
= 0.093, p = .911. 
5.2.3. Group Variations in Vulvovaginal Atrophy 
 Results from a chi-square test of independence indicated that women taking 
androgenic OCPs were significantly more likely to endorse vaginal bleeding associated 
with sexual activity than were women in the control group, χ2(2, 130) = 9.759, p = .007. 
Only one participant (1.69%) in the control group indicated they experience vaginal 
bleeding, whereas ten participants (20%) in the androgenic provided positive responses. A 
similar phenomenon was exhibited by women in the antiandrogenic group, with three 
participants (14.28%) endorsing vaginal bleeding associated with sexual activity. Analyses 
of the residuals, however, indicated that results from the antiandrogenic group were not 
significant, possibly due to the smaller group size (n = 21). 
A MANOVA indicated no significant between-group differences for any of the 
remaining Vulvovaginal Atrophy Assessment items (i.e., dryness, itching/irritation, 
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dysuria, or pain), F(2, 250) = 1.098, p = .365, and an ANOVA confirmed there were no 
differences in the total score, F(2) = 2.093, p = .127. Given there was no association 
between group and dryness nor pain, the finding that vaginal bleeding was significantly 
elevated suggests that aspects of OCPs unrelated to vaginal dryness may also be at play. 
Refer to Table 14 for a summary of these results. 
Table 14. 
Item-Level Analysis of the Vulvovaginal Atrophy Assessment by Study Group 
 Control N = 59 
Androgenic 
N = 50 
Antiandrogenic 
N = 21 
VVA item n % n % n % 
Bleeding 1 1.69 10 20.00 3 14.28 
 M SD M SD M SD 
Dryness 1.47 0.59 1.52 0.70 1.80 0.92 
Itching/Irritation 1.37 0.61 1.62 0.69 1.52 0.67 
Dysuria 1.13 0.39 1.18 0.43 1.14 0.35 
Pain 1.40 0.59 1.62 0.75 1.52 0.60 
Total score 5.38 1.56 5.94 1.59 6.00 1.58 
 
Note: VVA = Vulvovaginal Atrophy Assessment; M = mean; SD = standard deviation. Bleeding 
was assessed using a binary Yes/No response. The numbers presented in this Table reflect positive 
(i.e., “yes”) responses to the presence of vaginal bleeding associated with sexual activity. A 
significantly greater proportion of women in the androgenic group reported experiencing vaginal 
bleeding associated with sexual activity compared to women in either of the other two groups. 
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5.2.4. Group Variations in Positive Sexuality 
The average score on the Positive Sexuality Survey for all study participants was 
24.50 (SD = 4.56), which indicates that, on average, women who participated in this study 
had relatively positive views about their sexual activity. Overall, the three groups of women 
reported similar, positive views, with women in the control group reporting average scores 
of 24.84 (SD = 4.46). Similarly, women in the androgenic group reporting average scores 
of 24.70 (SD = 4.44), and women in the antiandrogenic group reporting average scores of 
23.09 (SD = 5.05). An ANOVA found no significant between-group difference for this 
measure, F(2) = 1.218, p = .299. It appears as though, despite physiological hindrances of 





CHAPTER 6: DISCUSSION 
6.1. GENERAL OVERVIEW 
Genital sexual arousal in women, which principally consists of vaginal 
vasocongestion and lubrication, is critical to healthy sexual function and is intricately 
linked with hormone function. Estrogens play a key role in regulating women’s genital 
arousal response (as reviewed in Santoro, Worsley, Miller, Parish, & Davis, 2016) and, as 
androgens are precursors in the biosynthesis of estrogens, androgens are also inherently 
integral to women’s sexual function (as reviewed in Davis, Worsley, Miller, Parish, & 
Santoro, 2016). It is therefore likely that alterations in hormone levels may lead to 
alterations in sexual function. 
Women may have sub- or supraphysiological levels of sex steroid hormones for a 
variety of reasons, including age (i.e., menopause), various medical conditions, and the use 
of hormonal contraceptives (Cohen & Goldstein, 2016). Oral contraceptive pills (OCPs), 
which are used by over a quarter of reproductive-age women in the United States (Daniels 
et al., 2015; Jones et al., 2013), contain either both ethinylestradiol and a synthetic 
progestin, or solely a synthetic progestin. Through progestin-induced hepatic increases in 
sex hormone binding globulin (SHBG), OCPs have been found to reduce the number of 
bioavailable androgens within women’s bodies (Zimmerman et al., 2014). Oral 
contraceptive pills have also been associated with diminished self-reported sexual function 
(Hassanin et al., 2018; Pazandeh et al., 2017; Wallwiener et al., 2015; Zethraeus et al., 
2016), increased vaginal dryness and vaginal pain (Smith et al., 2014), and decrements in 
objective measures of vaginal tissue integrity (Battaglia et al., 2012). This was the first 
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study to examine SHBG as a mediator of differences in vaginal blood flow and lubrication 
in women taking specific OCPs. 
The primary aim of this dissertation was to examine differences in physiological 
vaginal blood flow and lubrication among women using OCPs containing low doses (i.e., 
≤25 μg) of ethinylestradiol coupled with either an androgenic or antiandrogenic progestin. 
Serum concentrations of SHBG were also collected. Results from this study indicate there 
are physiological sexual side effects of OCPs based on pill androgenicity and related 
changes in SHBG concentrations. This dissertation also examined differences in self-
reported and clinician-assessed sexual function among the groups of women, finding that 
the presence of physiologically based sexual arousal dysfunction was more prevalent in the 
group of women taking antiandrogenic OCPs compared to the other two study groups. 
6.2. SUMMARY OF RESULTS 
It was hypothesized that physiological indices of sexual arousal would vary by 
hormonal state. Indeed, this was found to be the case. Women taking OCPs containing 
antiandrogenic progestins exhibited significantly lower levels of vaginal pulse amplitude 
(VPA) and lubrication compared to women taking androgenic OCPs or women in the 
control group. Responses on these measures for women taking OCPs containing 
androgenic progestins fell between women taking antiandrogenic OCPs and women in the 
control group, with the control group displaying the greatest physiological sexual arousal 
responses. Similarly, baseline (i.e., unaroused) levels of vaginal lubrication were 
significantly lower for women taking antiandrogenic OCPs than for women in the control 
group. Decrements in levels of post-film (i.e., aroused) lubrication were evidenced in 
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women taking both forms of OCPs; women in these two groups had significantly lower 
lubrication responses compared to women in the control group. These results indicate that 
OCPs containing ≤25 μg ethinylestradiol negatively impact women’s physiological sexual 
arousal responses, and this is particularly true for OCPs containing antiandrogenic 
progestins. These findings bolster previous research suggesting that progestin components 
within hormonal contraceptives are highly influential in women’s sexual functioning (e.g., 
Battaglia et al., 2012; Pazandeh et al., 2017; Zethraeus et al., 2016). 
It was also hypothesized that the observed decrements in physiological sexual 
arousal would be mediated by changes in serum SHBG concentrations. Oral hormonal 
contraceptive pill use increases the hepatic production of SHBG and consequently 
decreases the amount of circulating, or free, androgens (as reviewed in Casey, 
MacLaughlin, & Faubion, 2016). Oral contraceptive pills also suppress androgen 
production from the ovaries (Burrows & Goldstein, 2013), thus having dual pathways 
leading to antiandrogenic effects. Despite significant relationships among study group, 
SHBG levels, and physiological sexual arousal, SHBG was not found to meaningfully 
mediate this relationship in the present study. That is, SHBG did significantly partially 
mediate several of the study’s findings, though these effects were overshadowed by the 
strength of the preexisting relationships among the variables included in each model. 
Rather, a significant “chain reaction” appears to be at play, such that SHBG increased to 
varying extents based on women’s hormonal profiles, which then led to significant 
between-group differences in physiological sexual arousal, but additional variables are 
needed to explain these relationships. 
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It is possible that a model containing both SHBG and androgen level as mediating 
variables may yield significant results. The increase in SHBG caused by the androgenicity 
of various progestins is not, directly, the cause of poor sexual function. Rather, bound 
androgens (i.e., androgens that have bound to SHBG) are rendered inactive and cannot 
interact with genital tissue and facilitate sexual arousal (for reviews relevant to OCP use, 
see Casado-Espada, de Alarcón, de la Iglesia-Larrad, Bote-Bonaechea, & Montejo, 2019; 
Palacios & Lilue, 2018). It is therefore plausible that a model containing androgen levels 
in addition to SHBG may be more likely to fully mediate the relationship between OCP 
use and physiological sexual arousal. 
In opposition to these observed decrements in physiological sexual arousal, women 
taking OCPs displayed significantly greater subjective sexual arousal throughout the films. 
One possible explanation for this effect is that the sample of women taking OCPs may have 
been more sexually liberal and familiar with sexual films. As such, they may have been 
more mentally arousable to the sexual stimuli used in this study. Indeed, research has 
shown that, compared to naturally-cycling women, women taking OCPs report being more 
sexually experienced, holding less restrictive sexual morals, having greater interest in 
erotic material, and higher psychosexual motivation and enjoyment (Bancroft, Sherwin, 
Alexander, Davidson, & Walker, 1991). 
Alternatively, it is possible that these observed effects were due to hormonal 
influences on women’s attention to sexual stimuli. Eye-tracking studies indicate that both 
the content women attend to during exposure to sexual stimuli and the subjective ratings 
of attractiveness of this content vary based on OCP use. For example, naturally-cycling 
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women have been found to spend more time, and have a higher probability of, looking at 
genitals compared to women using OCPs, regardless of menstrual phase (Rupp & Wallen, 
2007). Women taking OCPs, on the other hand, have been found to spend more time 
looking at, and have a higher probability of, looking at contextual aspects of sexual scenes 
(e.g., background images, clothing; Rupp & Wallen, 2007). Research has also shown that 
naturally-cycling women rate scenes that have a greater focus on the genitals as more 
arousing than do OCP users (Rupp & Wallen, 2009). It is, therefore, possible that films 
containing less content that directly focuses on the genitals may be less subjectively 
sexually arousing to naturally-cycling women. Retrospective review of the sexual stimuli 
used in the present study showed that, through my efforts to use sexual stimuli that would 
be considered “female-friendly” and sexually pleasing to an array of women, the majority 
of time within the sexual films did not focus explicitly on the genitals. On average, 554 
seconds of the sexual film contained the actors’ whole or mostly whole bodies, whereas 
there were, on average, only 46 seconds dedicated to close-up scenes of the genitals. As 
such, levels of subjective sexual arousal may have been influenced by the hormonal 
regulation of women’s attention to the sexual stimuli. 
We also hypothesized that differences in sexual function would be minimal and that 
the observed physiological decrements would not necessarily indicate the presence of 
sexual dysfunction. This hypothesis was largely supported. We found no between-group 
differences in self-reported sexual function as measured by the Female Sexual Function 
Index, suggesting that there were no overwhelming, global effects of OCP use on sexual 
function in this sample. Though this finding is consistent with the pattern of results found 
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in the present study (i.e., that physiological decrements occur in the absence of perceived 
sexual dysfunction), this finding contradicts past research that has found both increases 
(Çetin et al., 2015) and decreases (Wallwiener et al., 2015) in sexual function. It is possible 
that, given the relatively young age of the study participants, women in this dissertation 
had not been experiencing OCP-induced sexual arousal difficulties for a long enough 
period of time to experience a more global impact on their sexual function. For example, 
it may be that more chronic OCP-induced arousal difficulties might lead to repeated 
uncomfortable or unsatisfying sexual activity and/or feelings of concern surrounding 
lubrication, which may, in turn, lead to reduced desire to engage in sexual activity. This 
hypothesis aligns with Basson’s (2000) circular model of sexual function, which suggests 
that engagement in positive sexual encounters may increase desire, whereas engagement 
in negative or unsatisfying sexual encounters may decrease desire for future sexual activity. 
Whereas the literature is mixed with regards to self-reported non-physiological 
aspects of sexual function (e.g., desire; A. R. Davis & Castaño, 2004; Pastor, Holla, & 
Chmel, 2013; Roberts, Cobey, Klapilová, & Havlíček, 2013), a review of the literature 
indicated that decreases in lubrication, increases in vestibular pain, and thinning of the labia 
minora and vaginal introitus are common among combined OCP users (Burrows et al., 
2012). In line with this extant literature, measures within the present study that more 
directly assessed physiological aspects of sexual arousal, particularly vaginal bleeding and 
lubrication (i.e., the Vulvovaginal Atrophy Assessment and clinical interview), yielded 
significant effects of OCPs on physiological sexual function. This continues to suggest that 
the sexual side effects of OCPs may primarily be organic in nature. 
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The high rates of vaginal bleeding after sexual activity found in the present study 
are likely due to the thinning of the vaginal tissue and/or cervical alterations. There is a 
high density of androgen receptors within the vaginal tissue, indicating that testosterone is 
essential for the maintenance of healthy tissue (I. Goldstein, 2009). As such, reductions in 
androgen levels (as observed in women taking OCPs; Zimmerman et al., 2014) may 
negatively impact the vaginal epithelium. Furthermore, vaginal tissue is also responsive to 
estrogen. It is possible that OCP use may lead to vaginal tissue atrophy through differences 
in responsiveness to naturally-occurring estrogen (i.e., 17β-estradiol) and synthetic 
ethinylestradiol (for a synthesis of the research examining hormones and genital tissue, see 
I. Goldstein, 2009). In other words, vaginal tissue may be more responsive to 17β-estradiol 
and less responsive to synthetic ethinylestradiol, thus leading to thinner vaginal tissue. 
Thinner tissue is more likely to lead to vaginal tearing and thus bleeding (Kagan & Rivera, 
2018) and is a possible explanation for the increased rates of bleeding associated with 
sexual activity seen in the present study. 
Women taking OCPs are also more likely to experience cervical ectopy and 
inflammation (Bright et al., 2011; Ocak et al., 2007). Cervical ectopy, which refers to when 
cells from within the cervical canal are present on the outside surface of the cervix, and 
cervical inflammation have both been linked with vaginal bleeding after sexual intercourse 
(Patil & Sharma, 2017). In a 12-month longitudinal study examining, in part, the effects of 
hormonal contraceptives on genital tissue, Bright and associates (2011) found large areas 
of cervical ectopy in 17.4% of women taking OCPs. These findings are supported by 
previous cross-sectional (Critchlow et al., 1995; Goldacre et al., 1978; Mali, Hunter, 
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Maggwa, & Tukei, 1995) and longitudinal (Louv, Austin, Perlman, & Alexander, 1989; 
Rahm, Gnarpe, & Odlind, 1988) research, and aligns well with the prevalence of vaginal 
bleeding in the current study (17.14% for the androgenic and antiandrogenic groups, 
combined). It is, therefore, possible that cervical ectopy contributed to the observed rates 
of vaginal bleeding. 
It is worth noting that the effects observed in the present study are likely 
conservative. In an attempt to approximate the hormonal profiles of women taking OCPs, 
all study sessions for naturally-cycling women were conducted within the luteal phase of 
the menstrual cycle. However, as sexual function is closely linked to hormone expression 
(S. R. Davis et al., 2016; Worsley, Santoro, Miller, Parish, & Davis, 2016), aspects of 
women’s sexual function vary across the menstrual cycle. For example, rates of sexual 
fantasy and desire are higher during the follicular compared to luteal phase (S. G. Brown 
et al., 2011; Dawson et al., 2012), as well as sexual arousal, engagement in sexual activity, 
and rates of orgasm (S. G. Brown et al., 2011; Caruso et al., 2014; Clayton et al., 1999; 
Graham et al., 2000). By this nature, it is likely that greater differences in sexual arousal 
and function would have been observed had study sessions for naturally-cycling women 
been conducted within the follicular phase. 
6.3. IMPLICATIONS 
This dissertation has several important clinical and methodological implications. 
First, the present research helps clarify variations in both physiological and self-reported 
(i.e., subjective sexual arousal and perceived genital arousal) sexual arousal among women 
taking OCPs with differing hormonal profiles. Second, as all OCPs included in this study 
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contained low doses of ethinylestradiol, we were able to parse apart the specific effects of 
the androgenic properties on women’s sexual arousal responses. Not only does this 
research enhance our understanding of the effects of OCPs on vaginal blood flow, a 
commonly examined marker of genital sexual arousal, but it also elucidates the effects of 
OCPs on physiological vaginal lubrication, a marker typically examined via self-report. 
Third, examining the mechanistic role of SHBG in these relationships helps to explain how 
such effects occur, as well as enhances our understanding of the important role testosterone 
plays in women’s physiological sexual arousal responses. To my knowledge, this was the 
first study to examine variations in physiological measures of vaginal lubrication among 
women taking OCPs. 
6.3.1. Clinical Implications 
Decrements in both vaginal blood flow and lubrication were observed in women in 
both OCP groups, providing empirical support for negative physiological sexual side 
effects of these medications. This finding has implications for OCP prescription and 
management; women at risk for sexual arousal dysfunction (e.g., diagnosed with diabetes, 
heart disease; McCabe et al., 2016) should be prescribed OCPs, particularly antiandrogenic 
OCPs, with caution and thorough consultation of relevant sexual side effects. For women 
taking OCPs who present with sexual arousal dysfunction, clinicians should assess the 
androgenicity of the pill and make changes to alter the woman’s hormonal profile to allow 
for a greater amount of free testosterone. 
One manner in which clinicians may choose to alter women’s levels of free 
testosterone is through dehydroepiandrosterone supplement. Indeed, one study examining 
 116 
the effect of a drospirenone-containing OCP (i.e., an antiandrogenic OCP) co-administered 
with dehydroepiandrosterone suggested such a combination may improve OCP-related 
reductions in sexual function (Zimmerman et al., 2015). In this study, 99 women were 
randomized to receive daily doses of 3 mg drospirenone coupled with 30 μg 
ethinylestradiol in conjunction with either 50 mg dehydroepiandrosterone or placebo. 
Though no significant effects were found for the dehydroepiandrosterone group, trends 
towards improved sexual function were noted. The authors concluded that, whereas 50 mg 
dehydroepiandrosterone restored total testosterone to pre-OCP levels, free testosterone was 
only restored by 47%. It may be necessary to restore completely women’s levels of free 
testosterone to see significant and clinically meaningful improvements in sexual function. 
It is important to note, however, that this study did not examine physiological changes in 
the genital tract or sexual function. It is therefore unknown whether any improvements in 
sexual function through dehydroepiandrosterone supplementation would translate from 
those seen in women’s self-reports to organic and/or physiological improvements. A case 
study has, however, reported improvements to the vulvar vestibule in a woman with OCP-
induced vaginal pain after OCP cessation and local administration of testosterone and 
estradiol (A. T. Goldstein, Burrows, & Goldstein, 2010). 
Alternatively, clinicians may suggest an OCP containing estradiol valerate, a 
synthetic, though considered natural and bioidentical, form of estrogen. The estradiol 
valerate plus dienogest OCP has been found to have good contraceptive efficacy (Endrikat 
et al., 2008; Palacios et al., 2010) and cycle control (Ahrendt, Makalová, Parke, Mellinger, 
& Mansour, 2009). Natural estradiol is a less stable compound than synthetic 
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ethinylestradiol and, therefore, increases SHBG concentrations to a lesser extent (Millán 
& Castañeda, 2014). Indeed, several studies have examined estradiol valerate-induced 
hepatic protein synthesis and have consistently found less pronounced changes in SHBG 
and other hepatic-related syntheses compared to that of ethinylestradiol (Junge, Mellinger, 
Parke, & Serrani, 2011; Klipping et al., 2011; Lindberg, Crona, Stigendal, Teger-Nilsson, 
& Silfverstolpe, 1989; Wiegratz, Lee, Kutschera, Winkler, & Kuhl, 2004). It is, therefore, 
possible that an estradiol valerate-containing OCP may impact sexual arousal and overall 
function to a lesser extent than ethinylestradiol-containing OCPs. Several studies have, in 
fact, found enhancing effects of the estradiol valerate plus dienogest OCP on sexual 
function (Caruso et al., 2016; Di Carlo et al., 2014; Osmanaǧaoǧlu, Atasaral, Baltaci, & 
Bozkaya, 2006), with one study finding no difference between this OCP and an androgenic 
OCP containing ethinylestradiol plus levonorgestrel (S. R. Davis et al., 2013). For patients 
who struggle with OCP-induced sexual dysfunction who wish to remain on an OCP, 
transitioning to an estradiol valerate-containing OCP may be advisable. 
Finally, the finding that women taking OCPs frequently endorsed vaginal bleeding 
with sexual activity is also clinically relevant. It is unknown whether this may be due to 
tearing of the vaginal tissue, cervical alterations, or through additional OCP-induced 
changes. Both vaginal tearing and cervical ectopy increase the likelihood of contracting 
sexually transmitted infections (e.g., Fethers, Fairley, Hocking, Gurrin, & Bradshaw, 2008; 
Srinivasan et al., 2012). In fact, a recent systematic review found cervical ectopy to be 
positively associated with numerous sexually transmitted infections, such as human 
papillomavirus, human immunodeficiency virus, and bacterial vaginosis (Soares, Braz, 
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Araújo, & Oliveira, 2019). This is problematic as women taking OCPs are less likely to 
also use barrier methods than those who are not. Cross-cultural research has demonstrated 
that only about 12-23% of women using hormonal contraceptives also use condoms during 
sexual activity (Centers for Disease Control and Prevention, 2012; Chibwesha et al., 2011; 
Eisenberg, Allsworth, Zhao, & Peipert, 2012; Harvey, Henderson, & Branch, 2004) and 
are therefore at greater risk for contracting an infection. Women taking OCPs should be 
counseled on this increased risk and encouraged to use barrier methods in addition to their 
OCP to reduce the likelihood of contracting an infection. 
6.3.2. Methodological Implications 
Results from this study also have methodological implications for sexual 
psychophysiological researchers. Based on these results, researchers within this area are 
urged to carefully consider the inclusion of women taking OCPs (especially when 
heterogeneously included), as the stark differences in physiological responding could mask 
true effects within the data and lead to inaccurate conclusions. Few sexual 
psychophysiological studies currently control for hormonal contraceptive use despite 
reporting that these were used by members of the sample (e.g., Bird, Seehuus, Clifton, & 
Rellini, 2014; Both et al., 2015; Velten, Scholten, Graham, Adolph, & Margraf, 2016). 
Furthermore, several studies fail to report whether participants were taking hormonal 
contraceptives altogether (e.g., Huberman, Suschinsky, Lalumière, & Chivers, 2013; 
Klein, Hill, Chang, Hillard, & Gorzalka, 2012; Vilarinho et al., 2014). When researchers 
do examine potential differences in women who are and are not taking OCPs, the 
composition of the OCP is not always considered (e.g., Brom et al., 2016; Suschinsky & 
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Lalumière, 2012). Results from the present research indicate that it is critical OCP use be 
taken into consideration when designing and recruiting for studies of this nature. There are 
striking differences in VPA between women taking androgenic and antiandrogenic OCPs. 
Failing to screen for this information and/or analyze separately could hinder research 
outcomes by masking true effects. 
6.4. LIMITATIONS 
This study has a few limitations that warrant mention. First, the majority of women 
who participated were heterosexual (74.61%) and college-aged (M = 20.12 years, SD = 
2.53). Though these demographic groups are the most likely to use OCPs and thus this 
study maps on nicely to these particular populations (Daniels et al., 2015; Jones et al., 
2013), many non-heterosexual and non-college-aged women do use OCPs. The application 
of the results of this study to less-represented populations is limited.  
Another limitation of this research is that the lubrication test strip was self-
administered. Although caution was taken when instructing participants where and how to 
insert the test strip to minimize between-person variability, it is possible that not all 
participants inserted the test strip correctly. This could have interfered with the accuracy 
of these particular data and potentially impacted the study results. Ideal circumstances 
would have been for a researcher to administer the measure to the participant, but this was 
not feasible to do within the setting in which the study took place. Relatedly, though 
extreme efforts were taken to match the four erotic films for content, some women likely 
found certain films more arousing than others. It is possible, though unlikely, that 
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preferences for certain settings or certain actors contributed to the observed differences in 
genital or subjective arousal. 
Finally, women in the control group likely had varying hormonal profiles, some of 
which may have looked similar to those of women in either of the two OCP groups. Though 
all study sessions for naturally-cycling women were conducted during the luteal phase of 
their menstrual cycle to minimize such hormonal differences, each woman likely had 
different estrogen, progesterone, and androgen levels, which could have interfered with the 
collected data. Indeed, research employing commercial immunoassays suggests that 
concentrations of serum estradiol ranges between 20 and 80 picograms per milliliter 
(pg/mL) during the follicular phase of the menstrual cycle, peaks at a range of 200 to 500 
pg/mL during preovulation, and plummets after ovulation occurs (Hobeika et al., 2020). 
Serum progesterone, contrastingly, is low during the follicular phase, with average levels 
of less than 1.5 nanograms per milliliter (ng/mL). Levels peak around ovulation and are 
usually greater than 7 ng/mL during the luteal phase, with some experts suggesting that 
levels as high as 15 ng/mL are indicative of normal luteal function. Testosterone levels are 
more consistent, with typical ranges between 20 and 50 nanograms per deciliter (Hobeika 
et al., 2020). Such ranges have implications for varying SHBG concentrations and, 
according to the results of the present study, physiological sexual arousal. Future research 
should more closely examine sexual function as it relates to naturally occurring variations 
in hormone levels. 
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6.5. FUTURE DIRECTIONS 
The results of this research indicate that OCPs influence the physiological 
responding of genital tissue. However, as this study was not prospective or randomized in 
design, it is possible that participants self-selected into their study groups. That is to say, 
many women (19; 26.76%) in the two OCP groups reported past use of a different OCP, 
with some women citing side effects (both sexual and nonsexual in nature) as their reasons 
for these changes. Alternatively, some women selected their OCP based on the side-effect 
profile. For example, OCPs containing antiandrogenic progestins are often prescribed to 
women wishing to alleviate concerns such as acne and/or oily skin (e.g., Lortscher, 
Admani, Satur, & Eichenfield, 2016). Though the possibility for self-selection does not 
cast a great deal of doubt onto the results of the present study, future research should 
employ prospective, randomized clinical trials to minimize the potential for such bias.  
In addition to prospective, randomized clinical trials, our understanding of the 
effects of OCPs on women’s bodies would be greatly enhanced through the use of long-
term follow-up and discontinuation studies. There is research to suggest that the 
physiological effects of OCPs may not be entirely reversible or may endure for an unknown 
period of time after discontinuation. In a cross-sectional study, Panzer and colleagues 
(2006) examined SHBG concentrations in 124 premenopausal women who were at 
different stages of OCP use: no history of OCP use, current OCP use, and past OCP use. 
Consistent with the present study, SHBG concentrations in the current OCP users were, on 
average, four times higher than those of women who have never used OCPs. A decrease in 
SHBG was noted in the group of women who had discontinued OCP use, though they 
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remained significantly elevated compared to women with no history of OCP use. This 
effect was found at a minimum of 120 days post-discontinuation. A separate study 
examining SHBG and androgen levels in eight women with polycystic ovarian syndrome 
found SHBG, testosterone, and dehydroepiandrosterone sulfate had returned to pre-OCP 
levels 8 weeks after discontinuation (Sánchez et al., 2007). It is important to note, however, 
that women in these two studies used OCPs for drastically different amounts of time: OCP 
users and discontinuers in the Panzer et al. study were required to have used OCPs for at 
least 6 months, whereas women in Sánchez et al. took OCPs for 3 months. It is, therefore, 
possible that it takes longer for androgen and SHBG concentrations to return to pre-OCP 
levels with longer OCP use. This speculation warrants research attention; many women in 
the present study reported many years (maximum of 5 years) of continuous OCP use. 
Sex hormone binding globulin was not found to mediate the relationship between 
OCP use and physiological sexual arousal, though it was very strongly associated with each 
of these variables. Future research should examine downstream hormonal changes as 
potential mediators of this relationship. It is possible that androgen levels may be a more 
suitable candidate mediator, as the hypothesized mechanism of action for SHBG on 
physiological sexual arousal is through decreased androgen levels. 
It would also be worth examining the degree to which physiological sexual arousal 
varies in women using OCPs with high doses (i.e., ≥30 μg) of ethinylestradiol compared 
to women taking OCPs with low doses (i.e., ≤25 μg) of ethinylestradiol or those who are 
naturally-cycling. It is likely that high doses of ethinylestradiol would negatively influence 
physiological sexual arousal for a number of reasons. Research examining the effects of 
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exogenously administered estradiol on vaginal tissue growth and structure found that 
subphysiological (5 μg) doses of estradiol were superior (i.e., facilitated greater tissue 
growth) to supraphysiological (45 μg) doses (Pessina et al., 2006). In this study, rats were 
ovariectomized and provided with continuous estradiol infusions of varying concentrations 
for two weeks. Greater tissue growth was observed in both the vaginal epithelium and 
muscularis (i.e., the outer and middle layers of the vaginal wall) in rats that had received 
the subphysiological doses of estradiol. Thick vaginal tissue is beneficial as it is less 
susceptible to abrasion, infection, and disturbances in sensation (Mac Bride et al., 2010). 
Furthermore, thick vaginal tissue is thought to allow for greater blood flow due to increases 
in the number and density of blood vessels and capillary beds (Mac Bride et al., 2010). 
Estrogen also stimulates SHBG production, and greater amounts of SHBG leads to 
fewer bioavailable androgens. As such, greater levels of estrogen should lead to a greater 
increase in SHBG, which would, in turn, lead to lesser amounts of bioavailable androgens 
and, in line with the results of the present study, poorer physiological sexual arousal. 
Indeed, research has found that OCPs containing low doses of ethinylestradiol are linked 
with lower levels of SHBG than are OCPs containing high doses of ethinylestradiol 
(Zimmerman et al., 2014). Therefore, future research should examine the extent to which 
physiological sexual arousal is impacted in women taking OCPs containing high doses of 
ethinylestradiol. 
6.6. CONCLUSION 
To my knowledge, this was the first study to compare multiple measures of 
physiological sexual arousal across groups of women taking OCPs with varying hormonal 
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profiles. The current study helps elucidate the relationship between progestin androgenicity 
and genital arousal function; antiandrogenic progestins had deleterious effects on vaginal 
blood flow and lubrication Compared to naturally-cycling women, women taking 
androgenic progestins also exhibited dampened physiological responses. Self-reported 
vaginal dryness and bleeding, as well as clinical assessments of female sexual arousal 
disorder, were also notably elevated in women taking OCPs. Furthermore, as the naturally-
cycling women were assessed during the luteal phase of their menstrual cycle, the between-
group differences observed in the present study are likely conservative; greater differences 
are likely to occur mid-cycle. These findings expand our understanding of the effect of 
hormones on genital tissue function and the physiological sexual side effects of OCPs and 






APPENDIX A: CONTRACEPTIVE HISTORY 
 
Form of contraceptive:    Pill     Other 
Name of Pill: ____________________________________________________________ 
Dose of ethinylestradiol: ___________________________________________________ 
Progestin name and dose: ___________________________________________________ 
When did you begin using this OCP: __________________________________________ 
Have you used other forms of hormonal contraceptives? 
  Yes     No   
If yes, list names and years used: _______________________________________ 
________________________________________________________________________ 






APPENDIX B: FEMALE SEXUAL DYSFUNCTION DIAGNOSIS 
 
 
Have you ever 
experienced… 
What are you experiencing 
now? 
How important is it for you to feel this 
during sexual activity? 
pleasurable sexual feelings in 
your genitals from stimulation 
of your genital area? 
 
□ Yes   □ No    
□ Same as in the past 
□ Lower intensity 
□ No longer experiencing this 
1 = Not important 
2 = Moderately unimportant 
3 = About equally important/unimportant 
4 = Moderately important 
5 = Very important 
genital pulsing or throbbing? 
 
 
□ Yes   □ No    
□ Same as in the past 
□ Lower intensity 
□ No longer experiencing this 
1 = Not important 
2 = Moderately unimportant 
3 = About equally important/unimportant 
4 = Moderately important 
5 = Very important 
genital or clitoral fullness, 
pressure or engorgement? 
 
□ Yes   □ No    
□ Same as in the past 
□ Lower intensity 
□ No longer experiencing this 
1 = Not important 
2 = Moderately unimportant 
3 = About equally important/unimportant 
4 = Moderately important 




□ Yes   □ No    
□ Same as in the past 
□ Lower intensity 
□ No longer experiencing this 
1 = Not important 
2 = Moderately unimportant 
3 = About equally important/unimportant 
4 = Moderately important 
5 = Very important 




□ Yes   □ No    
□ Same as in the past 
□ Lower intensity 
□ No longer experiencing this 
1 = Not important 
2 = Moderately unimportant 
3 = About equally important/unimportant 
4 = Moderately important 
5 = Very important 
 
Question Response 
Based on your responses to these 
questions, do you think you have an 
arousal problem now (difficulty getting or 
staying aroused)? 
□ Yes           □ No 
If yes…  
1. Do your arousal difficulties occur in: 
□ All types of situations (e.g., during 
partnered sexual activity AND 
masturbation) 
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□ Certain types of situations 
2. Was there ever a time when you were 
able to get and stay sexually aroused? 
□ Yes           □ No 
3. For how long have you been 
experiencing these arousal difficulties? 
_____years _____months 
4. Is this distressing to you? □ Yes           □ No 
5. If so, why is distressing to you? 
□ Because it makes my partner unhappy, 
frustrated, or distressed 
□ Because it makes me unhappy, 




For OCP groups: 
If she reports any difficulties with sexual arousal, ask:  
1. Did these difficulties begin before or after you began using the form of oral 
contraceptive that you are currently taking? 
□ Yes           □ No 
2. Do you believe these difficulties are related to your OCP in any way? 
□ Yes           □ No 










Please use the following scale to evaluate how you currently feel. Please answer 
honestly and carefully. On the scale, circle the number which best describes how you 
currently feel from 1 (not at all) to 7 (intensely). 
 
 
Currently, I feel:  
                                  Not at all                                                                 Intensely   
               
1. Warmth in genitals________________  
 
1 2 3 4 5 6 7 
2. Genital wetness or lubrication______ 
  
1 2 3 4 5 6 7 
3. Genital pulsing or throbbing_____________ 
 
1 2 3 4 5 6 7 
4. Genital tenseness or tightness___________ 
 
1 2 3 4 5 6 7 
5. Any genital feeling___________ 1 2 3 4 5 6 7 
 
 
6. IF you are currently 
experiencing any of the above 
sensations, to what extent are 
they:  






























…………......negative for you?  
 
1 2 3 4 5 6 7 
………uncomfortable for you?  
 
1 2 3 4 5 6 7 
…………….. positive for you? 
 
1 2 3 4 5 6 7 
…………..distressing for you? 
 
1 2 3 4 5 6 7 
……………appealing for you? 
 
1 2 3 4 5 6 7 





Currently, I feel: 
                                                Not at all                                                                 Intensely   
               
7. Sexually aroused________________  
 
1 2 3 4 5 6 7 
8. Mental sexual arousal_________ 
  
1 2 3 4 5 6 7 
9. Sexually turned off_____________ 
 





Please use the following scale to evaluate how you felt during your film session. Please 
answer honestly and carefully. On the scale, circle the number which best describes how 
you felt during the film from 1 (not at all) to 7 (intensely). 
 
 
During the film, I felt:  
                                 Not at all                                                                 Intensely   
               
1. Warmth in genitals________________  
 
1 2 3 4 5 6 7 
2. Genital wetness or lubrication______ 
  
1 2 3 4 5 6 7 
3. Genital pulsing or throbbing_____________ 
 
1 2 3 4 5 6 7 
4. Genital tenseness or tightness___________ 
 
1 2 3 4 5 6 7 
5. Any genital feeling___________ 1 2 3 4 5 6 7 
 
 
6. IF you experienced any of the 
above sensations, to what 
extent were they:  






























…………......negative for you?  
 
1 2 3 4 5 6 7 
………uncomfortable for you?  
 
1 2 3 4 5 6 7 
…………….. positive for you? 
 
1 2 3 4 5 6 7 
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…………..distressing for you? 
 
1 2 3 4 5 6 7 
……………appealing for you? 
 
1 2 3 4 5 6 7 
……………… sexual for you? 1 2 3 4 5 6 7 
 
 
During the film, I felt: 
                                               Not at all                                                                 Intensely   
               
7. Sexually aroused________________  
 
1 2 3 4 5 6 7 
8. Mental sexual arousal_________ 
  
1 2 3 4 5 6 7 
9. Sexually turned off_____________ 
 




APPENDIX D: DEMOGRAPHICS 
 
 
1. What is your date of birth? (month/day/year) _______________ 
 
2. What is your age? _______________ years  
 
3. What is your menopausal status? 
__Premenopausal 




4. Are you currently taking an oral contraceptive pill? 
Yes  No 
a. If yes, please write out the exact name of your oral contraceptive as it 
appears on your prescription, including any information on dose: 
b. If no, please list the form of contraception you use (e.g., condoms), if any: 
 
5. Are you currently taking any other prescription medications? 
Yes  No 
a. If yes, please list them below: 
 
6. Are you currently taking any non-prescription medications (e.g., vitamins)?  
Yes  No 
a. If yes, please list them below: 
 
7. Please indicate you highest level of education: 
__Some high school or less 
__High school graduate/GED 
__Some college 
__4 years college 
__Advanced degree (Ph.D., M.S., J.D., etc.) 
 
8. What is your yearly household income? 
__Less than $50,000 
__$50,001 to $100,000 
__More than $100,000 
 
9. Please indicate your ethnicity:          Hispanic/Latina          Not Hispanic/Latina 
  
10. The country of your heritage: ________________ 
  







__Pacific Islander/Hawaiian Native 
__Middle Eastern 
__Other; please specify 
 
12. What, if any, are your religious beliefs? You may only select one, so please 
choose which you most identify with. 
__Not religious 
__Atheist / Agnostic 













13. Please indicate your relationship status: 
__Single, not dating 
__Single, dating 
__In a committed relationship (with one partner) 
__In a committed relationship (with multiple partners) 
__Living with a partner 
__Married 
__Other, please specify 
   
14. If you are in a relationship, please indicate the duration of your current 
relationship: ________ 
 
15.  What sexual orientation do you identify with?  




___ Homosexual, Gay, Lesbian 
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___ Asexual 
___ I prefer not to identify my sexual orientation with a label. 
___ Other, please specify 
 
16. How old were you when you first had consensual sex with a partner (e.g., vaginal 
intercourse or however you define sex)? ________ years 
 
17. Have you ever experienced unwanted or non-consensual sexual activity (e.g., oral 
sex, vaginal intercourse, genital fondling)?  
Yes  No 
a. If yes, at what age(s) did this occur? 
 
18. How often do you use lubricants (e.g., KY Jelly) for vaginal intercourse? 
a. 5 = Almost always or always 
b. 4 = Most times (more than half the time) 
c. 3 = Sometimes (about half the time) 
d. 2 = A few times (less than half the time) 
e. 1 = Almost never or never 
 
19. For you, how acceptable is it to use lubricants (e.g., KY Jelly) for vaginal 
intercourse? 
a. 5 = Completely acceptable 
b. 4 = More acceptable than unacceptable 
c. 3 = Neutral 
d. 2 = More unacceptable then acceptable 





APPENDIX E: CONTRACEPTIVE SIDE EFFECTS 
Below is a list of possible side effects of various oral contraceptive pills. Please endorse 
as many of the side effects that you have experienced over the past 3 months.  
If you can clearly attribute any of the below side effects to reasons other than your oral 
contraceptive pill (e.g., weight loss due to dieting, decreases in acne due to a new skin 
care routine), please do not endorse them. 
 
  
1. Intermenstrual spotting 14. Decreases in mood (e.g., sadness) 
2. Lighter menstrual periods 15. Improvements in mood 
3. Heavier menstrual periods 16. Headaches or migraines 
4. Missed periods 17. Blurred vision 
5. Fewer or weaker menstrual cramps 18. Increased acne 
6. More or stronger menstrual 
cramps 
19. Decreased acne 
20. Breast tenderness 
7. Blood clots 21. Decreased libido/sexual desire/interest 
8. Nausea 
9. Bloating 
22. Increased libido/sexual desire/interest 
23. Vaginal discharge 
10. Weight gain 
11. Weight loss 
12. Increased appetite 
13. Decreased appetite 
24. Vaginal dryness 
25. Other (please specify) 
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APPENDIX F: FEMALE SEXUAL FUNCTION INDEX 
 
These questions ask about your sexual feelings and responses during the past 4 weeks. 
Please answer the following questions as honestly and clearly as possible. In answering 
these questions the following definitions apply: 
 
Sexual activity includes intercourse, caressing, foreplay, masturbation, deep kissing and 
petting. 
 
Sexual intercourse is defined as penetration (entry) of the vagina. 
 
Sexual stimulation includes situations like foreplay with a partner, self-stimulation 
(masturbation), or sexual fantasy. 
 
CIRCLE ONLY ONE CHOICE PER QUESTION: 
 
Sexual desire or interest is a feeling that included wanting to have a sexual experience, 
feeling receptive to a partner’s sexual initiation, and thinking or fantasizing about having 
sex. 
 
1. Over the past 4 weeks, how often did you feel sexual 




5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
  
2. Over the past 4 weeks, how would you rate your level 
(degree) of sexual desire or interest? 
5 = Very high 
4 = High  
3 = Moderate 
2 = Low 
1 = Very low or none at all 
  
3. Over the past 4 weeks, how often did you feel sexually 
aroused ("turned on") during sexual activity or 
intercourse? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
  
4. Over the past 4 weeks, how would you rate your level 
of sexual arousal ("turn on") during sexual activity or 
intercourse? 
 
5 = Very high 
4 = High  
3 = Moderate 
2 = Low 
1 = Very low or none at all 
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5. Over the past 4 weeks, how confident were you about 
becoming sexually aroused during sexual activity or 
intercourse? 
 
5 = Very high confidence 
4 = High confidence 
3 = Moderate confidence 
2 = Low confidence 
1 = Very low or no confidence 
  
6. Over the past 4 weeks, how often have you been 
satisfied with your arousal (excitement) during sexual 
activity or intercourse? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
  
7. Over the past 4 weeks, how often did you become 
sexually aroused (lubricated or "wet") during sexual 
activity or intercourse? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
  
8. Over the past 4 weeks, how difficult was it to become 
aroused (lubricated or “wet") during sexual activity or 
intercourse? 
 
1 = Extremely difficult or impossible 
2 = Very difficult 
3 = Difficult 
4 = Slightly difficult 
5 = Not difficult 
  
9. Over the past 4 weeks, how often did you maintain 
your arousal (lubrication or "wetness") until 
completion of sexual activity or intercourse? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
  
10. Over the past 4 weeks, how difficult was it to maintain 
your arousal (lubrication or "wetness") until 
completion of sexual activity or intercourse? 
 
1 = Extremely difficult or impossible 
2 = Very difficult 
3 = Difficult 
4 = Slightly difficult 
5 = Not difficult 
  
11. Over the past 4 weeks, when you had sexual 
stimulation or intercourse, how often did you reach 
orgasm (climax)? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
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12. Over the past 4 weeks, when you had sexual 
stimulation or intercourse, how difficult was it for you 
to reach orgasm (climax)? 
1 = Extremely difficult or impossible 
2 = Very difficult 
3 = Difficult 
4 = Slightly difficult 
5 = Not difficult 
  
13. Over the past 4 weeks, how satisfied were you with 
your ability to reach orgasm (climax) during sexual 
activity or intercourse? 
5 = Very satisfied 
4 = Moderately satisfied 
3 = About equally satisfied and 
dissatisfied 
2 = Moderately dissatisfied 
1 = Very dissatisfied 
  
14. Over the past 4 weeks, how satisfied have you been 
with the amount of emotional closeness during sexual 
activity between you and your partner? 
 
5 = Very satisfied 
4 = Moderately satisfied 
3 = About equally satisfied and 
dissatisfied 
2 = Moderately dissatisfied 
1 = Very dissatisfied 
  
15. Over the past 4 weeks, how satisfied have you been 
with your sexual relationship with your partner? 
 
5 = Very satisfied 
4 = Moderately satisfied 
3 = About equally satisfied and 
dissatisfied 
2 = Moderately dissatisfied 
1 = Very dissatisfied 
  
16. Over the past 4 weeks, how satisfied have you been 
with your overall sexual life? 
 
5 = Very satisfied 
4 = Moderately satisfied 
3 = About equally satisfied and 
dissatisfied 
2 = Moderately dissatisfied 
1 = Very dissatisfied 
  
17. Over the past 4 weeks, how often did you experience 
discomfort or pain during vaginal penetration? 
 
1 = Almost always or always 
2 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
4 = A few times (less than half the time) 
5 = Almost never or never 








18. Over the past 4 weeks, how often did you experience 
discomfort or pain following vaginal penetration? 
 
1 = Almost always or always 
2 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
4 = A few times (less than half the time) 
5 = Almost never or never 
N/A = No vaginal penetration 
  
19. Over the past 4 weeks, how would you rate your level 
(degree) of discomfort or pain during or following 
vaginal penetration? 
 
N/A = No sexual activity 1 = Very high 
2 = High  
3 = Moderate 
4 = Low 
5 = Very low or none at all 
N/A = No vaginal penetration 
 139 
APPENDIX G: FEMALE SEXUAL DISTRESS SCALE - REVISED 
 
In the last week, how often did you feel…  
 
 Never Rarely Occasionally Frequently Always 
1. Distressed about your sex life 0 1 2 3 4 
2. Unhappy about your sexual relationship 0 1 2 3 4 
3. Guilty about sexual difficulties 0 1 2 3 4 
4. Frustrated by your sexual problems 0 1 2 3 4 
5. Stressed about sex 0 1 2 3 4 
6. Inferior because of sexual problems 0 1 2 3 4 
7. Worried about sex 0 1 2 3 4 
8. Sexually inadequate 0 1 2 3 4 
9. Regrets about your sexuality 0 1 2 3 4 
10. Embarrassed about sexual problems 0 1 2 3 4 
11. Dissatisfied with your sex life 0 1 2 3 4 
12. Angry about your sex life 0 1 2 3 4 





APPENDIX H: VULVOVAGINAL ATROPHY ASSESSMENT 
 
To what extent do you experience each of the following… 
 
 None Mild Moderate Severe 
1. Vaginal dryness 0 1 2 3 
2. Vaginal and/or vulvar 
irritation/itching 
0 1 2 3 
3. Dysuria (painful or difficult 
urination) 
0 1 2 3 
4. Vaginal pain associated with sexual 
activity 
0 1 2 3 
 
Do you experience… 
 
1. Vaginal bleeding associated with sexual 
activity  




APPENDIX I: POSITIVE SEXUALITY SURVEY 
 










I have felt confident in my 
ability to become 
lubricated/“wet” during 
sexual arousal. 
1 2 3 4 5 6 
I have felt satisfied with 
my ability to become 
lubricated/“wet” during 
sexual arousal. 
1 2 3 4 5 6 
After engaging in sexual 
activity, I have felt 
positively about (or 
pleased with) my ability to 
perform sexually. 
1 2 3 4 5 6 
I have felt positively about 
(or pleased with) my 
overall sexual life. 
1 2 3 4 5 6 
My sexual experiences 
have felt rewarding. 




GLOSSARY OF TERMS 
Androgenic: The extent to which sex hormone binding globulin is upregulated, leading to 
an increase in this protein and a decrease in androgen levels. In the present context, a 
relative androgenicity of >.5mg 
Androgenicity: The extent to which physiological reactions similar to those produced by 
androgens are present. In the present context, the extent to which sex hormone binding 
globulin is upregulated 
Antiandrogenic: The extent to which sex hormone binding globulin is upregulated, 
leading to an increase in this protein and a decrease in androgen levels. In the present 
context, a relative androgenicity of ≤.5mg 
Ethinylestradiol: A synthetic derivative of the natural estrogen 17β-estradiol. It is found 
in nearly all combined forms of oral contraceptive pills 
Female sexual arousal disorder: Defined by DSM-IV-TR as a persistent or recurrent 
inability to attain or maintain an adequate lubrication-swelling response until completion 
of sexual activity, must cause persistent or marked distress or interpersonal difficulty 
Sex hormone binding globulin: A protein produced by the liver. It binds tightly to the sex 
steroid hormones estrogen, dihydrotestosterone, and testosterone, rendering them inactive 
Subjective sexual arousal: The cognitive or emotional experience of sexual arousal; 
feeling “turned on” in one’s mind 
Vaginal pulse amplitude: A psychophysiological index that reflects short-term changes 
in the engorgement of blood in the vaginal tissue; an index of women’s physiological, or 
genital, arousal  
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